<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3184032/results/search/disease/results.xml">
  <result pre="on Antimicrobial Therapy Antiviral Drugs for Viruses Other Than Human" exact="Immunodeficiency" post="Virus RazonableRaymund R.MD[], Address correspondence to Raymund R. Razonable,"/>
  <result pre="R.MD[], Address correspondence to Raymund R. Razonable, MD, Division of" exact="Infectious" post="Diseases, 200 First St SW, Rochester, MN 55905 (www.mayoclinicproceedings.com."/>
  <result pre="Rochester, MN 55905 (www.mayoclinicproceedings.com. ppub: 2011-10861010091026(C) , 20111009.pdf Abstract Most" exact="viral" post="diseases, with the exception of those caused by human"/>
  <result pre="viral diseases, with the exception of those caused by human" exact="immunodeficiency" post="virus, are self-limited illnesses that do not require specific"/>
  <result pre="exception of the antisense molecule fomivirsen, all antiherpes drugs inhibit" exact="viral" post="replication by serving as competitive substrates for viral DNA"/>
  <result pre="drugs inhibit viral replication by serving as competitive substrates for" exact="viral" post="DNA polymerase. Drugs for the treatment of influenza inhibit"/>
  <result pre="therapy with Interferon-α and ribavirin remains the backbone treatment for" exact="chronic hepatitis" post="C; the addition of serine protease inhibitors improves the"/>
  <result pre="with Interferon-α and ribavirin remains the backbone treatment for chronic" exact="hepatitis" post="C; the addition of serine protease inhibitors improves the"/>
  <result pre="protease inhibitors improves the treatment outcome of patients infected with" exact="hepatitis" post="C virus genotype 1. Chronic hepatitis B can be"/>
  <result pre="outcome of patients infected with hepatitis C virus genotype 1." exact="Chronic" post="hepatitis B can be treated with interferon or a"/>
  <result pre="of patients infected with hepatitis C virus genotype 1. Chronic" exact="hepatitis" post="B can be treated with interferon or a combination"/>
  <result pre="almost all the nucleos(t) ide analogues for the treatment of" exact="chronic hepatitis" post="B possess anti–human immunodeficiency virus properties, and they inhibit"/>
  <result pre="all the nucleos(t) ide analogues for the treatment of chronic" exact="hepatitis" post="B possess anti–human immunodeficiency virus properties, and they inhibit"/>
  <result pre="analogues for the treatment of chronic hepatitis B possess anti–human" exact="immunodeficiency" post="virus properties, and they inhibit replication of hepatitis B"/>
  <result pre="possess anti–human immunodeficiency virus properties, and they inhibit replication of" exact="hepatitis" post="B virus by serving as competitive substrates for its"/>
  <result pre="potential clinical applications, such as ribavirin for the treatment of" exact="chronic hepatitis" post="C and respiratory syncytial virus and cidofovir for the"/>
  <result pre="clinical applications, such as ribavirin for the treatment of chronic" exact="hepatitis" post="C and respiratory syncytial virus and cidofovir for the"/>
  <result pre="as ribavirin for the treatment of chronic hepatitis C and" exact="respiratory" post="syncytial virus and cidofovir for the treatment of cytomegalovirus"/>
  <result pre="The major mechanisms for drug resistance are mutations in the" exact="viral" post="DNA polymerase gene or in genes that encode for"/>
  <result pre="DNA polymerase gene or in genes that encode for the" exact="viral" post="kinases required for the activation of certain drugs such"/>
  <result pre="drugs such as acyclovir and ganciclovir. Widespread antiviral resistance has" exact="limited" post="the clinical utility of M2 inhibitors for the prevention"/>
  <result pre="provides an overview of clinically available antiviral drugs for the" exact="primary" post="care physician, with a special focus on pharmacology, clinical"/>
  <result pre="uses, and adverse effects. ALT = alanine aminotransferase; CHB =" exact="chronic hepatitis" post="B; CHC = chronic hepatitis C; CMV = cytomegalovirus;"/>
  <result pre="and adverse effects. ALT = alanine aminotransferase; CHB = chronic" exact="hepatitis" post="B; CHC = chronic hepatitis C; CMV = cytomegalovirus;"/>
  <result pre="= alanine aminotransferase; CHB = chronic hepatitis B; CHC =" exact="chronic hepatitis" post="C; CMV = cytomegalovirus; CSF = cerebrospinal fluid; EBV"/>
  <result pre="alanine aminotransferase; CHB = chronic hepatitis B; CHC = chronic" exact="hepatitis" post="C; CMV = cytomegalovirus; CSF = cerebrospinal fluid; EBV"/>
  <result pre="virus; FDA = US Food and Drug Administration; HBeAg =" exact="hepatitis" post="B e antigen; HBV = hepatitis B virus; HCV"/>
  <result pre="Drug Administration; HBeAg = hepatitis B e antigen; HBV =" exact="hepatitis" post="B virus; HCV = hepatitis C virus; HHV ="/>
  <result pre="B e antigen; HBV = hepatitis B virus; HCV =" exact="hepatitis" post="C virus; HHV = human herpesvirus; HIV = human"/>
  <result pre="hepatitis C virus; HHV = human herpesvirus; HIV = human" exact="immunodeficiency" post="virus; HSV = herpes simplex virus; HSV-1 = HSV"/>
  <result pre="= human herpesvirus; HIV = human immunodeficiency virus; HSV =" exact="herpes" post="simplex virus; HSV-1 = HSV type 1; HSV-2 ="/>
  <result pre="immunodeficiency virus; HSV = herpes simplex virus; HSV-1 = HSV" exact="type 1;" post="HSV-2 = HSV type 2; IFN = interferon; IV"/>
  <result pre="simplex virus; HSV-1 = HSV type 1; HSV-2 = HSV" exact="type 2;" post="IFN = interferon; IV = intravenous; mRNA= messenger RNA;"/>
  <result pre="= interferon; IV = intravenous; mRNA= messenger RNA; RSV =" exact="respiratory" post="syncytial virus; SC = subcutaneous; SVR = sustained virologic"/>
  <result pre="= sustained virologic response; TK = thymidine kinase; VZV =" exact="varicella" post="zoster virus Most diseases caused by viral pathogens are"/>
  <result pre="sustained virologic response; TK = thymidine kinase; VZV = varicella" exact="zoster" post="virus Most diseases caused by viral pathogens are self-limited"/>
  <result pre="kinase; VZV = varicella zoster virus Most diseases caused by" exact="viral" post="pathogens are self-limited and do not require specific antiviral"/>
  <result pre="require specific antiviral therapy. Other than therapies targeting the human" exact="immunodeficiency" post="virus (HIV), currently available antiviral drugs in the clinical"/>
  <result pre="other potential applications, such as ribavirin for the treatment of" exact="respiratory" post="syncytial virus (RSV) and cidofovir for the treatment of"/>
  <result pre="cidofovir for the treatment of cytomegalovirus (CMV) and other DNA" exact="viral" post="infections. Nucleos(t)ide analogues for the treatment of chronic hepatitis"/>
  <result pre="other DNA viral infections. Nucleos(t)ide analogues for the treatment of" exact="chronic hepatitis" post="B (CHB) may also possess anti-HIV properties, but their"/>
  <result pre="DNA viral infections. Nucleos(t)ide analogues for the treatment of chronic" exact="hepatitis" post="B (CHB) may also possess anti-HIV properties, but their"/>
  <result pre="Acyclovir Acyclovir is a synthetic guanosine analogue used for treating" exact="herpes" post="simplex virus (HSV) and varicella zoster virus (VZV) infections.1-3"/>
  <result pre="guanosine analogue used for treating herpes simplex virus (HSV) and" exact="varicella" post="zoster virus (VZV) infections.1-3 Intravenous (IV) acyclovir provides excellent"/>
  <result pre="analogue used for treating herpes simplex virus (HSV) and varicella" exact="zoster" post="virus (VZV) infections.1-3 Intravenous (IV) acyclovir provides excellent tissue"/>
  <result pre="glomerular filtration and tubular secretion. Herpesviruses have varying degrees of" exact="susceptibility to" post="acyclovir, with HSV type 1 (HSV-1) being most susceptible,"/>
  <result pre="Herpesviruses have varying degrees of susceptibility to acyclovir, with HSV" exact="type 1" post="(HSV-1) being most susceptible, followed by HSV type 2"/>
  <result pre="HSV type 1 (HSV-1) being most susceptible, followed by HSV" exact="type 2" post="(HSV-2) and VZV, and to a lesser extent Epstein-Barr"/>
  <result pre="be converted to acyclovir-triphosphate; this process is initially catalyzed by" exact="viral" post="thymidine kinase (TK) and subsequently by human enzymes. Acyclovir-triphosphate"/>
  <result pre="by human enzymes. Acyclovir-triphosphate serves as a competitive substrate for" exact="viral" post="DNA polymerase, and its incorporation into the DNA chain"/>
  <result pre="its incorporation into the DNA chain results in termination of" exact="viral" post="replication. Acyclovir is approved for the treatment of primary"/>
  <result pre="of viral replication. Acyclovir is approved for the treatment of" exact="primary" post="and recurrent genital HSV infection (Table 1).2,4,5 Topical acyclovir"/>
  <result pre="replication. Acyclovir is approved for the treatment of primary and" exact="recurrent" post="genital HSV infection (Table 1).2,4,5 Topical acyclovir may be"/>
  <result pre="approved for the treatment of primary and recurrent genital HSV" exact="infection" post="(Table 1).2,4,5 Topical acyclovir may be used to treat"/>
  <result pre="infection (Table 1).2,4,5 Topical acyclovir may be used to treat" exact="genital herpes," post="but the oral formulation is generally recommended6; IV acyclovir"/>
  <result pre="oral acyclovir is also indicated to reduce the incidence of" exact="recurrent" post="genital herpes.4,7 Oral acyclovir is modestly efficacious against orolabial"/>
  <result pre="is modestly efficacious against orolabial herpes. In immunocompetent individuals, orolabial" exact="herpes" post="is often self-limited, and antiviral treatment is generally not"/>
  <result pre="acyclovir may be indicated for severe cases, for those with" exact="recurrent" post="orolabial herpes, and in those who are immunocompromised.7,8 Intravenous"/>
  <result pre="HSV encephalitis9 and should be started as soon as the" exact="disease" post="is suspected clinically. Magnetic resonance imaging of the brain"/>
  <result pre="suspected clinically. Magnetic resonance imaging of the brain typically demonstrates" exact="temporal lobe" post="involvement, and diagnosis is confirmed by detection of HSV"/>
  <result pre="for the treatment of VZV11,12; however, young immunocompetent patients with" exact="zoster" post="may not require treatment if the lesions are localized"/>
  <result pre="with zoster may not require treatment if the lesions are" exact="localized" post="and have been present for more than 72 hours."/>
  <result pre="72 hours. Intravenous acyclovir is recommended for patients with disseminated" exact="zoster" post="disease or visceral involvement. Acyclovir treatment of zoster reduces"/>
  <result pre="hours. Intravenous acyclovir is recommended for patients with disseminated zoster" exact="disease" post="or visceral involvement. Acyclovir treatment of zoster reduces duration"/>
  <result pre="with disseminated zoster disease or visceral involvement. Acyclovir treatment of" exact="zoster" post="reduces duration of viral shedding, formation of new lesions,"/>
  <result pre="or visceral involvement. Acyclovir treatment of zoster reduces duration of" exact="viral" post="shedding, formation of new lesions, and short- and long-term"/>
  <result pre="may be added as an adjunct to acyclovir treatment of" exact="zoster" post="to improve quality of life, especially in elderly patients."/>
  <result pre="elderly patients. Acyclovir has been used in the treatment of" exact="acute" post="retinal necrosis (which is associated with HSV or VZV),"/>
  <result pre="acute retinal necrosis (which is associated with HSV or VZV)," exact="eczema" post="herpeticum, and oral hairy leukoplakia due to EBV. Oral"/>
  <result pre="(which is associated with HSV or VZV), eczema herpeticum, and" exact="oral hairy leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
  <result pre="is associated with HSV or VZV), eczema herpeticum, and oral" exact="hairy leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
  <result pre="associated with HSV or VZV), eczema herpeticum, and oral hairy" exact="leukoplakia" post="due to EBV. Oral acyclovir is used to prevent"/>
  <result pre="patients because of intratubular precipitation of acyclovir crystals. Acyclovir crystalline" exact="nephropathy" post="is more common when acyclovir is given as a"/>
  <result pre="function may reduce this risk. Reversible neurologic symptoms such as" exact="delirium" post="and seizures may occur rarely in elderly people and"/>
  <result pre="may reduce this risk. Reversible neurologic symptoms such as delirium" exact="and seizures" post="may occur rarely in elderly people and those with"/>
  <result pre="reduce this risk. Reversible neurologic symptoms such as delirium and" exact="seizures" post="may occur rarely in elderly people and those with"/>
  <result pre="rash.3,20,21 Acyclovir-resistant HSV has been reported, especially in immunocompromised patients.22-24" exact="Resistance" post="occurs by selection of viral mutants that are deficient"/>
  <result pre="reported, especially in immunocompromised patients.22-24 Resistance occurs by selection of" exact="viral" post="mutants that are deficient in TK (which results in"/>
  <result pre="highly active against HSV-1 and VZV.25,26 Brivudin is phosphorylated by" exact="viral" post="TK and cellular kinases to brivudin-triphosphate, which serves as"/>
  <result pre="kinases to brivudin-triphosphate, which serves as a competitive inhibitor of" exact="viral" post="DNA polymerase, thereby terminating viral DNA synthesis. It is"/>
  <result pre="as a competitive inhibitor of viral DNA polymerase, thereby terminating" exact="viral" post="DNA synthesis. It is available in some countries for"/>
  <result pre="It is available in some countries for the treatment of" exact="herpes zoster" post="and herpes simplex. However, concerns about its toxicity halted"/>
  <result pre="is available in some countries for the treatment of herpes" exact="zoster" post="and herpes simplex. However, concerns about its toxicity halted"/>
  <result pre="in some countries for the treatment of herpes zoster and" exact="herpes" post="simplex. However, concerns about its toxicity halted its clinical"/>
  <result pre="for the treatment of CMV, other herpesviruses, and other DNA" exact="viral" post="infections.27 It is available as an IV formulation, and"/>
  <result pre="concentrations.28 Direct intraocular injection of cidofovir is contraindicated due to" exact="ocular" post="hypotony.27 Serum cidofovir concentrations decline rapidly after IV infusion,"/>
  <result pre="phosphorylated by cellular kinases into cidofovir-diphosphate, a competitive substrate for" exact="viral" post="DNA polymerase, thereby halting viral DNA synthesis.27 The major"/>
  <result pre="cidofovir-diphosphate, a competitive substrate for viral DNA polymerase, thereby halting" exact="viral" post="DNA synthesis.27 The major clinical indication for cidofovir is"/>
  <result pre="The major clinical indication for cidofovir is the treatment of" exact="CMV retinitis" post="in HIV-infected patients (Table 1).31 Cidofovir is also used"/>
  <result pre="major clinical indication for cidofovir is the treatment of CMV" exact="retinitis" post="in HIV-infected patients (Table 1).31 Cidofovir is also used"/>
  <result pre="also used as rescue therapy for immunocompromised patients with CMV" exact="disease" post="resistant or unresponsive to ganciclovir.32 Because activation of cidofovir"/>
  <result pre="to ganciclovir.32 Because activation of cidofovir does not rely on" exact="viral" post="kinases, it retains activity against CMV with the UL97"/>
  <result pre="with the UL97 mutation and HSV with the TK mutation.33" exact="Resistance" post="to cidofovir occurs when the virus develops mutations in"/>
  <result pre="used off-label for various illnesses, such as acyclovir-resistant HSV disease," exact="condyloma acuminatum," post="BK virus–associated hemorrhagic cystitis, JC virus–associated progressive multifocal leukoencephalopathy,"/>
  <result pre="illnesses, such as acyclovir-resistant HSV disease, condyloma acuminatum, BK virus–associated" exact="hemorrhagic cystitis," post="JC virus–associated progressive multifocal leukoencephalopathy, and other infections due"/>
  <result pre="HSV disease, condyloma acuminatum, BK virus–associated hemorrhagic cystitis, JC virus–associated" exact="progressive multifocal leukoencephalopathy," post="and other infections due to double-stranded DNA viruses.34-47 TABLE"/>
  <result pre="virus–associated hemorrhagic cystitis, JC virus–associated progressive multifocal leukoencephalopathy, and other" exact="infections" post="due to double-stranded DNA viruses.34-47 TABLE 1. Suggested Antiviral"/>
  <result pre="severity of nephrotoxicity may be reduced by hydration and probenecid.48" exact="Blood" post="cell counts should be monitored to assess myelosuppression, and"/>
  <result pre="and ophthalmological surveillance is recommended because of the risk of" exact="ocular" post="hypotony, uveitis, and iritis.49,50 Famciclovir Famciclovir is a diacetyl"/>
  <result pre="Its mechanism of action is through penciclovir; penciclovir triphosphate inhibits" exact="herpes" post="DNA synthesis by acting as a substrate for viral"/>
  <result pre="inhibits herpes DNA synthesis by acting as a substrate for" exact="viral" post="DNA polymerase. The major clinical indications for famciclovir use"/>
  <result pre="The major clinical indications for famciclovir use are treatment of" exact="herpes zoster," post="recurrent genital herpes,52 and recurrent herpes labialis.53 Famciclovir can"/>
  <result pre="clinical indications for famciclovir use are treatment of herpes zoster," exact="recurrent" post="genital herpes,52 and recurrent herpes labialis.53 Famciclovir can also"/>
  <result pre="use are treatment of herpes zoster, recurrent genital herpes,52 and" exact="recurrent" post="herpes labialis.53 Famciclovir can also be used as suppression"/>
  <result pre="are treatment of herpes zoster, recurrent genital herpes,52 and recurrent" exact="herpes" post="labialis.53 Famciclovir can also be used as suppression therapy"/>
  <result pre="be used as suppression therapy to reduce the risk of" exact="recurrent" post="genital herpes as well as oral treatment of uncomplicated"/>
  <result pre="used as suppression therapy to reduce the risk of recurrent" exact="genital herpes" post="as well as oral treatment of uncomplicated varicella in"/>
  <result pre="as suppression therapy to reduce the risk of recurrent genital" exact="herpes" post="as well as oral treatment of uncomplicated varicella in"/>
  <result pre="recurrent genital herpes as well as oral treatment of uncomplicated" exact="varicella" post="in HIV-infected patients. The most common adverse effects of"/>
  <result pre="Rare adverse events include jaundice, rash, pruritus, somnolence, and confusion.54" exact="Acute" post="renal failure has occurred in patients taking inappropriately high"/>
  <result pre="adverse events include jaundice, rash, pruritus, somnolence, and confusion.54 Acute" exact="renal failure" post="has occurred in patients taking inappropriately high doses of"/>
  <result pre="potential mechanisms of antiviral activity include its nonspecific interactions with" exact="viral" post="particles that may prevent adsorption or lead to inhibition"/>
  <result pre="prevent adsorption or lead to inhibition of enzymes required for" exact="viral" post="DNA synthesis. Fomivirsen is given intravitreally. Its main indication"/>
  <result pre="is given intravitreally. Its main indication is the treatment of" exact="CMV retinitis" post="in patients with AIDS who have not benefited from"/>
  <result pre="given intravitreally. Its main indication is the treatment of CMV" exact="retinitis" post="in patients with AIDS who have not benefited from"/>
  <result pre="pressure and inflammation. Blurred vision, conjunctival hemorrhage, retinal detachment, and" exact="retinal edema" post="are other adverse effects.55-57 Foscarnet Foscarnet is a nonnucleoside"/>
  <result pre="excreted through glomerular filtration. Foscarnet selectively inhibits pyrophosphate binding on" exact="viral" post="DNA polymerases, thus suppressing HSV-1, HSV-2, and CMV replication."/>
  <result pre="UL97 kinase mutations.33 Foscarnet is approved for the treatment of" exact="CMV retinitis" post="in patients with AIDS.58 It has been used to"/>
  <result pre="kinase mutations.33 Foscarnet is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS.58 It has been used to"/>
  <result pre="in the glomerular capillary lumen.62,63 Foscarnet may cause myelosuppression, with" exact="anemia" post="as the most common effect. It can chelate bivalent"/>
  <result pre="with a bioavailability of only 5%.65 Management of active CMV" exact="disease" post="is therefore with IV ganciclovir or its oral valyl"/>
  <result pre="prodrug valganciclovir. Intravitreal ganciclovir implants are also available, with minimal" exact="systemic" post="absorption. Ganciclovir is excreted renally. Ganciclovir undergoes triphosphorylation to"/>
  <result pre="UL97-encoded kinase and subsequently by cellular kinases. Ganciclovir triphosphate inhibits" exact="viral" post="DNA synthesis through competitive incorporation during viral DNA synthesis,"/>
  <result pre="Ganciclovir triphosphate inhibits viral DNA synthesis through competitive incorporation during" exact="viral" post="DNA synthesis, thereby leading to DNA chain termination. In"/>
  <result pre="not against HHV-7.67 Ganciclovir is approved for the treatment of" exact="CMV retinitis" post="in patients with AIDS, the treatment of herpes simplex"/>
  <result pre="against HHV-7.67 Ganciclovir is approved for the treatment of CMV" exact="retinitis" post="in patients with AIDS, the treatment of herpes simplex"/>
  <result pre="of CMV retinitis in patients with AIDS, the treatment of" exact="herpes" post="simplex keratitis, and CMV prophylaxis in transplant recipients. Intravenous"/>
  <result pre="used to treat other forms of CMV disease, such as" exact="colitis" post="or esophagitis. Induction therapy with IV ganciclovir for CMV"/>
  <result pre="as colitis or esophagitis. Induction therapy with IV ganciclovir for" exact="CMV retinitis" post="in patients with AIDS has an efficacy of 85%"/>
  <result pre="colitis or esophagitis. Induction therapy with IV ganciclovir for CMV" exact="retinitis" post="in patients with AIDS has an efficacy of 85%"/>
  <result pre="be used for induction treatment of CMV disease.69 Because CMV" exact="disease" post="often recurs or progresses in patients with advanced AIDS,"/>
  <result pre="ganciclovir may also be surgically implanted for the treatment of" exact="CMV retinitis," post="although this treatment should be used together with systemic"/>
  <result pre="CMV retinitis, although this treatment should be used together with" exact="systemic" post="therapy with IV ganciclovir or oral valganciclovir therapy. Oral"/>
  <result pre="and oral ganciclovir have also been used to prevent CMV" exact="disease" post="in transplant recipients, valganciclovir is currently the preferred drug"/>
  <result pre="ganciclovir is also used as a first-line treatment of CMV" exact="disease" post="in bone marrow and solid organ transplant recipients.61 Reversible"/>
  <result pre="disease in bone marrow and solid organ transplant recipients.61 Reversible" exact="bone marrow suppression" post="is the most common adverse effect of ganciclovir. Other"/>
  <result pre="of serum creatinine and liver enzymes. Neurotoxicity may occur occasionally." exact="Resistance" post="to ganciclovir occurs most commonly in severely immunocompromised patients"/>
  <result pre="ganciclovir resistance is UL97 gene mutation71; this mutation leads to" exact="deficiency" post="in the viral kinase that is necessary for the"/>
  <result pre="UL97 gene mutation71; this mutation leads to deficiency in the" exact="viral" post="kinase that is necessary for the initial phosphorylation of"/>
  <result pre="is only available as topical therapy for mucocutaneous herpes. For" exact="systemic" post="use, penciclovir has been reformulated into the oral prodrug"/>
  <result pre="and subsequently by cellular kinases into active penciclovir-triphosphate, which inhibits" exact="herpes" post="DNA polymerase activity by serving as a competitive inhibitor"/>
  <result pre="of deoxyguanosine triphosphate.73 Penciclovir is approved as topical therapy for" exact="recurrent" post="herpes labialis, resulting in a faster healing rate and"/>
  <result pre="deoxyguanosine triphosphate.73 Penciclovir is approved as topical therapy for recurrent" exact="herpes" post="labialis, resulting in a faster healing rate and reduction"/>
  <result pre="in a faster healing rate and reduction in pain and" exact="viral" post="shedding.74 Valacyclovir Valacyclovir, an L-valyl ester prodrug of acyclovir,75"/>
  <result pre="acyclovir. It is approved for the treatment of initial or" exact="recurrent" post="episodes of genital herpes76 and for the treatment of"/>
  <result pre="recurrent episodes of genital herpes76 and for the treatment of" exact="recurrent" post="herpes labialis.4 Treatment is most efficacious when initiated at"/>
  <result pre="episodes of genital herpes76 and for the treatment of recurrent" exact="herpes" post="labialis.4 Treatment is most efficacious when initiated at the"/>
  <result pre="of symptoms.4 Suppressive therapy with valacyclovir is recommended to prevent" exact="recurrent" post="genital herpes76 and has the potential to reduce transmission"/>
  <result pre="to sexual partners.4 Valacyclovir is approved for treatment of VZV." exact="Varicella" post="often resolves without antiviral therapy in those who are"/>
  <result pre="was as effective as acyclovir, with similar resolution rates of" exact="cutaneous" post="zoster but accelerated resolution of herpetic pain and a"/>
  <result pre="as effective as acyclovir, with similar resolution rates of cutaneous" exact="zoster" post="but accelerated resolution of herpetic pain and a lower"/>
  <result pre="cutaneous zoster but accelerated resolution of herpetic pain and a" exact="lower" post="risk of postherpetic neuralgia.75 The typical course of zoster"/>
  <result pre="a lower risk of postherpetic neuralgia.75 The typical course of" exact="zoster" post="treatment is 7 days, and the first dose should"/>
  <result pre="in immunocompromised patients.77 Valacyclovir has also been used to treat" exact="acute" post="retinal necrosis and for prevention of CMV disease in"/>
  <result pre="to treat acute retinal necrosis and for prevention of CMV" exact="disease" post="in kidney transplant recipients.78 Although ganciclovir is the backbone"/>
  <result pre="for preventing CMV in heart, liver, lung, pancreas, and small" exact="bowel" post="transplant recipients. The adverse effects of valacyclovir are similar"/>
  <result pre="are similar to those of acyclovir. At very high doses," exact="neurotoxicity" post="characterized by confusion, hallucinations, and seizures may occur,78 especially"/>
  <result pre="acyclovir. At very high doses, neurotoxicity characterized by confusion, hallucinations," exact="and seizures" post="may occur,78 especially in elderly patients and in those"/>
  <result pre="At very high doses, neurotoxicity characterized by confusion, hallucinations, and" exact="seizures" post="may occur,78 especially in elderly patients and in those"/>
  <result pre="occur,78 especially in elderly patients and in those with dehydration" exact="and renal disease." post="The mechanism of resistance for valacyclovir is identical to"/>
  <result pre="especially in elderly patients and in those with dehydration and" exact="renal disease." post="The mechanism of resistance for valacyclovir is identical to"/>
  <result pre="its antiviral activity in the form of ganciclovir-triphosphate, which inhibits" exact="viral" post="replication by serving as a competitive substrate for CMV"/>
  <result pre="Valganciclovir was first approved by the FDA for treatment of" exact="CMV retinitis" post="in patients with AIDS.83 For immediate sight-threatening lesions, valganciclovir"/>
  <result pre="was first approved by the FDA for treatment of CMV" exact="retinitis" post="in patients with AIDS.83 For immediate sight-threatening lesions, valganciclovir"/>
  <result pre="intravitreal ganciclovir implant. Valganciclovir is also used for preventing CMV" exact="disease" post="in high-risk CMV donor-positive/recipient-negative recipients of kidney, heart, or"/>
  <result pre="the United States, valganciclovir is not approved for preventing CMV" exact="disease" post="in liver recipients because of a higher incidence of"/>
  <result pre="liver recipients because of a higher incidence of tissue-invasive CMV" exact="disease" post="in patients who received valganciclovir vs oral ganciclovir prophylaxis."/>
  <result pre="prophylaxis. In other countries, valganciclovir is used for preventing CMV" exact="disease" post="in all solid organ transplant recipients. It has recently"/>
  <result pre="It has recently gained approval for the prevention of CMV" exact="disease" post="in pediatric heart and kidney transplant recipients. It can"/>
  <result pre="gained approval for the prevention of CMV disease in pediatric" exact="heart" post="and kidney transplant recipients. It can also be used"/>
  <result pre="It can also be used to preemptively treat asymptomatic CMV" exact="infection" post="in transplant recipients.85-88 Valganciclovir was recently demonstrated to be"/>
  <result pre="effective as IV ganciclovir for treating mild to moderate CMV" exact="disease" post="in transplant recipients.86,87,89 Bone marrow suppression is the most"/>
  <result pre="manifestations, such as diarrhea, nausea, and vomiting, may be observed." exact="Resistance" post="to valganciclovir occurs through mechanisms identical to those underlying"/>
  <result pre="is currently available only as an ophthalmic solution for treating" exact="recurrent" post="epithelial keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its"/>
  <result pre="currently available only as an ophthalmic solution for treating recurrent" exact="epithelial" post="keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its active"/>
  <result pre="available only as an ophthalmic solution for treating recurrent epithelial" exact="keratitis" post="and acute keratoconjunctivitis.90 Once phosphorylated into its active form,"/>
  <result pre="as an ophthalmic solution for treating recurrent epithelial keratitis and" exact="acute" post="keratoconjunctivitis.90 Once phosphorylated into its active form, vidarabine inhibits"/>
  <result pre="acute keratoconjunctivitis.90 Once phosphorylated into its active form, vidarabine inhibits" exact="viral" post="DNA polymerase. Adverse effects of ophthalmic vidarabine include irritation,"/>
  <result pre="vidarabine include irritation, pain, photophobia, lacrimation, and occlusion of the" exact="lacrimal" post="duct.90 ANTIVIRAL DRUGS FOR INFLUENZA M2 Inhibitors Amantadine. Amantadine"/>
  <result pre="by about 1 day, if given within 48 hours of" exact="disease" post="onset.91 Amantadine is effective as prophylaxis for preventing symptomatic"/>
  <result pre="of disease onset.91 Amantadine is effective as prophylaxis for preventing" exact="symptomatic" post="influenza A infection in exposed persons.92,93 It is usually"/>
  <result pre="Amantadine is effective as prophylaxis for preventing symptomatic influenza A" exact="infection" post="in exposed persons.92,93 It is usually given for 14"/>
  <result pre="and those taking neuroaffective drugs. Emergence of amantadine resistance has" exact="limited" post="its use in the clinical setting.94,95 Amantadine resistance, characterized"/>
  <result pre="it inhibits the ion channel function of M2, thereby inhibiting" exact="viral" post="uncoating. Rimantadine is indicated for prevention and treatment of"/>
  <result pre="of influenza A virus93; however, its clinical utility is currently" exact="limited" post="by drug resistance.96,97 A few trials that compared amantadine"/>
  <result pre="excreted renally. Oseltamivir carboxylate, the active drug metabolite, selectively blocks" exact="viral" post="neuraminidase, thereby preventing the release of virus from infected"/>
  <result pre="children (≥1 year) and adults with influenza A or B" exact="viral" post="infections.98 Treatment should start within 48 hours of disease"/>
  <result pre="B viral infections.98 Treatment should start within 48 hours of" exact="disease" post="onset and continue for 5 days. Oseltamivir is as"/>
  <result pre="other neuraminidase inhibitor, zanamivir, in reducing the febrile period during" exact="infection" post="with influenza A (H1N1), influenza A (H3N2), and influenza"/>
  <result pre="statistically significant difference between oseltamivir and zanamivir prophylaxis for preventing" exact="symptomatic" post="influenza among immunocompetent adults.100 The most common adverse effects"/>
  <result pre="is poorly absorbed.106 Inhaled zanamivir produces high concentrations in the" exact="respiratory" post="tract where influenza virus infection occurs. About 4% to"/>
  <result pre="zanamivir produces high concentrations in the respiratory tract where influenza" exact="virus infection" post="occurs. About 4% to 20% of inhaled zanamivir is"/>
  <result pre="produces high concentrations in the respiratory tract where influenza virus" exact="infection" post="occurs. About 4% to 20% of inhaled zanamivir is"/>
  <result pre="inhibiting neuraminidase, which is essential for release of newly formed" exact="viral" post="particles from infected cells.106 For treatment, zanamivir is given"/>
  <result pre="critically ill patients with influenza.107,108 Inhaled zanamivir is well tolerated.106" exact="Acute" post="bronchospasm with decline in respiratory function has been reported;"/>
  <result pre="ill patients with influenza.107,108 Inhaled zanamivir is well tolerated.106 Acute" exact="bronchospasm" post="with decline in respiratory function has been reported; a"/>
  <result pre="Inhaled zanamivir is well tolerated.106 Acute bronchospasm with decline in" exact="respiratory" post="function has been reported; a bronchodilator should be available"/>
  <result pre="be available if given as treatment for patients with underlying" exact="pulmonary disease." post="Other adverse effects include headache and gastrointestinal symptoms. Hypersensitivity"/>
  <result pre="pulmonary disease. Other adverse effects include headache and gastrointestinal symptoms." exact="Hypersensitivity" post="reactions and neuropsychiatric adverse effects occur rarely.109 ANTIVIRAL DRUGS"/>
  <result pre="Interferons (IFNs) are naturally occurring proteins produced in response to" exact="viral" post="infection.110 The 3 major classes of IFNs are α,"/>
  <result pre="β, and γ; IFN-α and IFN-β are further classified as" exact="type I," post="whereas IFN-γ is type II.110 Available only in parenteral"/>
  <result pre="for target cells. Interferons have been used in treating multiple" exact="viral" post="infections and are most commonly used for treating chronic"/>
  <result pre="target cells. Interferons have been used in treating multiple viral" exact="infections" post="and are most commonly used for treating chronic viral"/>
  <result pre="multiple viral infections and are most commonly used for treating" exact="chronic" post="viral hepatitis.112 Interferon-α was the first drug approved for"/>
  <result pre="viral infections and are most commonly used for treating chronic" exact="viral" post="hepatitis.112 Interferon-α was the first drug approved for treatment"/>
  <result pre="Interferon-α was the first drug approved for treatment of compensated" exact="liver disease" post="due to CHB; it is not approved for treating"/>
  <result pre="was the first drug approved for treatment of compensated liver" exact="disease" post="due to CHB; it is not approved for treating"/>
  <result pre="disease due to CHB; it is not approved for treating" exact="acute hepatitis" post="B. For CHB, IFN α-2a or α-2b is given"/>
  <result pre="due to CHB; it is not approved for treating acute" exact="hepatitis" post="B. For CHB, IFN α-2a or α-2b is given"/>
  <result pre="48 weeks.112,113 Interferon was most effective in patients with recently" exact="acquired" post="hepatitis B virus (HBV), high pretreatment levels of alanine"/>
  <result pre="weeks.112,113 Interferon was most effective in patients with recently acquired" exact="hepatitis" post="B virus (HBV), high pretreatment levels of alanine aminotransferase"/>
  <result pre="Likewise, SC peginterferon-α may be more effective than lamivudine in" exact="hepatitis" post="B e antigen (HBeAg)–positive and HBeAg-negative patients with CHB,115-117"/>
  <result pre="enhance efficacy.118 Interferon-α is effective in patients with HBV and" exact="hepatitis" post="D virus coinfection,119 although they are less responsive than"/>
  <result pre="patients. Interferon-α-2a and -2b are approved for the treatment of" exact="chronic hepatitis" post="C (CHC); however, they are not approved for acute"/>
  <result pre="Interferon-α-2a and -2b are approved for the treatment of chronic" exact="hepatitis" post="C (CHC); however, they are not approved for acute"/>
  <result pre="chronic hepatitis C (CHC); however, they are not approved for" exact="acute hepatitis" post="C. A meta-analysis found that IFN-α for at least"/>
  <result pre="hepatitis C (CHC); however, they are not approved for acute" exact="hepatitis" post="C. A meta-analysis found that IFN-α for at least"/>
  <result pre="with IFN-α.128,129 Therefore, the British Society for Gastroenterology and the" exact="American" post="Association for the Study of Liver Diseases130 recommends once-weekly"/>
  <result pre="in patients not infected with HIV is 24 weeks (for" exact="hepatitis" post="C virus [HCV] genotype 2 or 3) or 48"/>
  <result pre="is higher and the rate of sustained virologic response (SVR)" exact="lower" post="than in patients infected with HCV alone.131-133 Use of"/>
  <result pre="and 12% for those treated with IFN-α plus ribavirin.132 A" exact="lower" post="SVR rate to combination peginterferon-α plus ribavirin therapy was"/>
  <result pre="ribavirin for 48 weeks. Interferons are generally not recommended in" exact="acute" post="viral hepatitis, but treatment of acute HCV with IFN-α"/>
  <result pre="for 48 weeks. Interferons are generally not recommended in acute" exact="viral hepatitis," post="but treatment of acute HCV with IFN-α has resulted"/>
  <result pre="generally not recommended in acute viral hepatitis, but treatment of" exact="acute" post="HCV with IFN-α has resulted in a more rapid"/>
  <result pre="a more rapid resolution of viremia and reduced progression to" exact="chronic" post="hepatitis.134,135 The American Association for the Study of Liver"/>
  <result pre="resolution of viremia and reduced progression to chronic hepatitis.134,135 The" exact="American" post="Association for the Study of Liver Diseases recommends either"/>
  <result pre="to chronic hepatitis.134,135 The American Association for the Study of" exact="Liver Diseases" post="recommends either IFN-α or peginterferon-α for at least 6"/>
  <result pre="chronic hepatitis.134,135 The American Association for the Study of Liver" exact="Diseases" post="recommends either IFN-α or peginterferon-α for at least 6"/>
  <result pre="either IFN-α or peginterferon-α for at least 6 months for" exact="acute" post="HCV if infection persists for 2 to 4 months"/>
  <result pre="peginterferon-α for at least 6 months for acute HCV if" exact="infection" post="persists for 2 to 4 months after diagnosis. Interferons"/>
  <result pre="after diagnosis. Interferons are also approved as intralesional therapy for" exact="condyloma acuminatum" post="of genital and perianal areas.136 Intralesional injection ensures relatively"/>
  <result pre="IFN at the local site of infection, but occurrence of" exact="systemic" post="adverse effects suggests its absorption from this site. Currently,"/>
  <result pre="keratitis.90 Beneficial responses to IFN-α have been reported for HIV-associated" exact="progressive multifocal" post="leukoencephalopathy138; however, these findings are debatable because IFN-α may"/>
  <result pre="Among the more serious adverse effects are neuropsychiatric disorders (eg," exact="depression" post="and homicidal and suicidal ideation), neurologic disturbances (eg, confusion"/>
  <result pre="homicidal and suicidal ideation), neurologic disturbances (eg, confusion and seizures)," exact="myelosuppression" post="(neutropenia [most commonly] and aplastic anemia [rarely]), cardiovascular disorders"/>
  <result pre="disturbances (eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and" exact="aplastic anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
  <result pre="(eg, confusion and seizures), myelosuppression (neutropenia [most commonly] and aplastic" exact="anemia" post="[rarely]), cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid"/>
  <result pre="and seizures), myelosuppression (neutropenia [most commonly] and aplastic anemia [rarely])," exact="cardiovascular" post="disorders (eg, arrhythmias), endocrine disorders (eg, thyroid disorders), and"/>
  <result pre="cardiovascular disorders (eg, arrhythmias), endocrine disorders (eg, thyroid disorders), and" exact="pulmonary" post="disorders (eg, dyspnea and pneumonitis).140-142 Patients at risk for"/>
  <result pre="disorders (eg, dyspnea and pneumonitis).140-142 Patients at risk for developing" exact="depression" post="are those with preexisting mood and anxiety disorders, those"/>
  <result pre="risk for developing depression are those with preexisting mood and" exact="anxiety" post="disorders, those with a history of major depression, and"/>
  <result pre="preexisting mood and anxiety disorders, those with a history of" exact="major depression," post="and those receiving higher doses of IFN-α or undergoing"/>
  <result pre="receiving higher doses of IFN-α or undergoing long-term treatment regimens." exact="Selective" post="serotonin reuptake inhibitors have been used successfully to treat"/>
  <result pre="Administration of aerosolized ribavirin leads to high concentrations in the" exact="respiratory" post="tract, with some ribavirin absorbed systemically. Ribavirin is mainly"/>
  <result pre="competitive inhibition, intracellular guanosine triphosphate pools are markedly reduced and" exact="viral" post="nucleic acid and protein synthesis are inhibited. Ribavirin does"/>
  <result pre="acid and protein synthesis are inhibited. Ribavirin does not alter" exact="viral" post="attachment, penetration, or uncoating, nor does it induce IFN"/>
  <result pre="its dose, may be dictated by HCV genotype. Treatment for" exact="infections" post="with HCV genotype 1, and probably with genotype 4,"/>
  <result pre="been used, off-label, for the treatment of HSV, influenza, severe" exact="acute" post="respiratory syndrome coronavirus,154,155 La Crosse encephalitis,156 Nipah encephalitis,157 Lassa"/>
  <result pre="used, off-label, for the treatment of HSV, influenza, severe acute" exact="respiratory" post="syndrome coronavirus,154,155 La Crosse encephalitis,156 Nipah encephalitis,157 Lassa fever,158"/>
  <result pre="off-label, for the treatment of HSV, influenza, severe acute respiratory" exact="syndrome" post="coronavirus,154,155 La Crosse encephalitis,156 Nipah encephalitis,157 Lassa fever,158 hemorrhagic"/>
  <result pre="renal syndrome,159 Crimean-Congo hemorrhagic fever,160,161 Bolivian hemorrhagic fever,162 and hantavirus" exact="pulmonary" post="syndrome.163 Aerosolized ribavirin can cause sudden deterioration of respiratory"/>
  <result pre="hantavirus pulmonary syndrome.163 Aerosolized ribavirin can cause sudden deterioration of" exact="respiratory" post="function and cardiovascular effects. Precipitation of inhaled ribavirin may"/>
  <result pre="Aerosolized ribavirin can cause sudden deterioration of respiratory function and" exact="cardiovascular" post="effects. Precipitation of inhaled ribavirin may occur in ventilatory"/>
  <result pre="effects. Precipitation of inhaled ribavirin may occur in ventilatory tubings." exact="Hemolytic" post="anemia occurs commonly,154 and ribavirin should not be given"/>
  <result pre="Precipitation of inhaled ribavirin may occur in ventilatory tubings. Hemolytic" exact="anemia" post="occurs commonly,154 and ribavirin should not be given to"/>
  <result pre="with preexisting medical conditions exacerbated by ribavirin-induced hemolysis, including significant" exact="cardiac disease" post="or hemoglobinopathies. Severe depression, suicidal ideation, and relapse of"/>
  <result pre="preexisting medical conditions exacerbated by ribavirin-induced hemolysis, including significant cardiac" exact="disease" post="or hemoglobinopathies. Severe depression, suicidal ideation, and relapse of"/>
  <result pre="exacerbated by ribavirin-induced hemolysis, including significant cardiac disease or hemoglobinopathies." exact="Severe" post="depression, suicidal ideation, and relapse of drug abuse may"/>
  <result pre="disease or hemoglobinopathies. Severe depression, suicidal ideation, and relapse of" exact="drug abuse" post="may occur, and ribavirin is contraindicated in patients with"/>
  <result pre="patients considered for treatment with these drugs be tested for" exact="HIV infection," post="and monotherapy with these drugs should be avoided for"/>
  <result pre="for HIV-infected patients to reduce the risk of HIV resistance." exact="Hepatitis" post="B virus may also develop resistance to these drugs,"/>
  <result pre="defined, and HBV relapse often occurs after discontinuation of treatment." exact="Severe" post="exacerbation of hepatitis may also occur on discontinuation of"/>
  <result pre="relapse often occurs after discontinuation of treatment. Severe exacerbation of" exact="hepatitis" post="may also occur on discontinuation of these drugs; hence,"/>
  <result pre="monitoring for hepatotoxicity should be performed after stopping treatment. Lactic" exact="acidosis" post="may occur with nucleos(t)ide analogues, and the drugs should"/>
  <result pre="tubular secretion. TABLE 2. Antiviral Nucleos(t)ides for the Treatment of" exact="Chronic" post="Hepatitis Ba Adefovir is converted intracellularly by cellular kinases"/>
  <result pre="secretion. TABLE 2. Antiviral Nucleos(t)ides for the Treatment of Chronic" exact="Hepatitis" post="Ba Adefovir is converted intracellularly by cellular kinases to"/>
  <result pre="anti-HBV drugs, it has been used in adults with decompensated" exact="liver disease," post="or with compensated liver disease with evidence of active"/>
  <result pre="used in adults with decompensated liver disease, or with compensated" exact="liver disease" post="with evidence of active viral replication, persistently elevated ALT"/>
  <result pre="in adults with decompensated liver disease, or with compensated liver" exact="disease" post="with evidence of active viral replication, persistently elevated ALT"/>
  <result pre="disease, or with compensated liver disease with evidence of active" exact="viral" post="replication, persistently elevated ALT levels, and histologic evidence of"/>
  <result pre="The major adverse effect of adefovir is nephrotoxicity, including proximal" exact="renal tubular" post="dysfunction and Fanconi syndrome. Gastrointestinal symptoms, such as nausea,"/>
  <result pre="of adefovir is nephrotoxicity, including proximal renal tubular dysfunction and" exact="Fanconi syndrome." post="Gastrointestinal symptoms, such as nausea, diarrhea, and abdominal pain,"/>
  <result pre="and peak serum concentrations occur in 1.0 to 1.5 hours." exact="Hepatic" post="metabolism is low, and up to 70% is excreted"/>
  <result pre="metabolite, lamivudine triphosphate. When the active metabolite is incorporated into" exact="viral" post="DNA by HBV polymerase, it results in DNA chain"/>
  <result pre="pain, nausea, and headache. The clinical utility of lamivudine is" exact="limited" post="by the rapid development of antiviral resistance. Lamivudine shares"/>
  <result pre="development of antiviral resistance. Lamivudine shares with the L-nucleosides the" exact="primary" post="resistance mutation, rtM204V/I, which occurs easily and confers cross-resistance."/>
  <result pre="to 50 hours.179 Telbivudine-triphosphate inhibits HBV by competitive inhibition of" exact="viral" post="DNA polymerase. Oral telbivudine is approved for the treatment"/>
  <result pre="approved for the treatment of CHB in patients with compensated" exact="liver disease" post="and evidence of active viral replication, persistently increased serum"/>
  <result pre="for the treatment of CHB in patients with compensated liver" exact="disease" post="and evidence of active viral replication, persistently increased serum"/>
  <result pre="in patients with compensated liver disease and evidence of active" exact="viral" post="replication, persistently increased serum ALT concentrations, and histologic evidence"/>
  <result pre="persistently increased serum ALT concentrations, and histologic evidence of active" exact="liver inflammation" post="and fibrosis.180,181 It is considered more effective than lamivudine"/>
  <result pre="dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are" exact="peripheral neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
  <result pre="fatigue, gastrointestinal symptoms, and rash. Unique adverse effects are peripheral" exact="neuropathy" post="and myopathy with elevation in creatine kinase levels. Telbivudine"/>
  <result pre="gastrointestinal symptoms, and rash. Unique adverse effects are peripheral neuropathy" exact="and myopathy" post="with elevation in creatine kinase levels. Telbivudine treatment should"/>
  <result pre="symptoms, and rash. Unique adverse effects are peripheral neuropathy and" exact="myopathy" post="with elevation in creatine kinase levels. Telbivudine treatment should"/>
  <result pre="creatine kinase levels. Telbivudine treatment should be discontinued if either" exact="peripheral neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
  <result pre="kinase levels. Telbivudine treatment should be discontinued if either peripheral" exact="neuropathy" post="or myopathy is diagnosed. The rate of resistance to"/>
  <result pre="Telbivudine treatment should be discontinued if either peripheral neuropathy or" exact="myopathy" post="is diagnosed. The rate of resistance to telbivudine is"/>
  <result pre="with the natural substrate deoxyadenosine 5′-triphosphate for incorporation into the" exact="viral" post="DNA strand. Tenofovir is used for the treatment of"/>
  <result pre="effects of tenofovir include gastrointestinal symptoms, dizziness, fatigue, and headache." exact="Renal" post="toxicities, including nephritis, proximal renal tubulopathy (including Fanconi syndrome),"/>
  <result pre="toxicities, including nephritis, proximal renal tubulopathy (including Fanconi syndrome), and" exact="renal failure," post="have been associated with tenofovir.189-193 Primary tenofovir resistance mutations"/>
  <result pre="Fanconi syndrome), and renal failure, have been associated with tenofovir.189-193" exact="Primary" post="tenofovir resistance mutations have not been well defined. Although"/>
  <result pre="rates between 38% and 46%, and the rate is even" exact="lower" post="among black patients. Hence, major efforts have been made"/>
  <result pre="binding reversibly to the HCV nonstructural 3 protein, ultimately inhibiting" exact="viral" post="replication. In a recently conducted phase 3 international randomized"/>
  <result pre="previously untreated black and nonblack adults with HCV genotype 1" exact="infection" post="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition"/>
  <result pre="were boceprevir use, previous relapse (compared with previous nonresponder), low" exact="viral" post="load at baseline, and absence of cirrhosis.196 Boceprevir (800"/>
  <result pre="(compared with previous nonresponder), low viral load at baseline, and" exact="absence of" post="cirrhosis.196 Boceprevir (800 mg 3 times daily) was approved"/>
  <result pre="anemia.194 The addition of boceprevir nearly doubled the rate of" exact="anemia" post="compared with the use of standard peginterferon and ribavirin"/>
  <result pre="kind of rash.199 Rashes can be mild to severe, and" exact="Stevens-Johnson syndrome" post="and drug rash with eosinophilia and systemic symptoms have"/>
  <result pre="of rash.199 Rashes can be mild to severe, and Stevens-Johnson" exact="syndrome" post="and drug rash with eosinophilia and systemic symptoms have"/>
  <result pre="severe, and Stevens-Johnson syndrome and drug rash with eosinophilia and" exact="systemic" post="symptoms have been reported. Telaprevir therapy should be discontinued"/>
  <result pre="rash or even mild to moderate rash if accompanied by" exact="systemic" post="symptoms. The mechanism underlying rash development is unknown.199 Fatigue,"/>
  <result pre="their clinical utility for most infections, such as acyclovir for" exact="herpes" post="simplex virus and ganciclovir for CMV. However, other of"/>
  <result pre="options for the prevention and treatment of influenza virus, including" exact="infections" post="with resistant strains; and (3) discuss antiviral drugs for"/>
  <result pre="strains; and (3) discuss antiviral drugs for the treatment of" exact="chronic hepatitis" post="B and C infections, including novel nucleos(t)ide analogues and"/>
  <result pre="and (3) discuss antiviral drugs for the treatment of chronic" exact="hepatitis" post="B and C infections, including novel nucleos(t)ide analogues and"/>
  <result pre="respectively. References REFERENCES 1.CoreyLFifeKHBenedettiJKet al.Intravenous acyclovir for the treatment of" exact="primary" post="genital herpes. Ann Intern Med. 1983;98:914-9216305244 2.NilsenAEAasenTHalsosAMet al.Efficacy of"/>
  <result pre="References REFERENCES 1.CoreyLFifeKHBenedettiJKet al.Intravenous acyclovir for the treatment of primary" exact="genital herpes." post="Ann Intern Med. 1983;98:914-9216305244 2.NilsenAEAasenTHalsosAMet al.Efficacy of oral acyclovir"/>
  <result pre="al.Efficacy of oral acyclovir in the treatment of initial and" exact="recurrent" post="genital herpes. Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of herpes zoster"/>
  <result pre="of oral acyclovir in the treatment of initial and recurrent" exact="genital herpes." post="Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of herpes zoster infections: use"/>
  <result pre="initial and recurrent genital herpes. Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of" exact="herpes zoster" post="infections: use in children undergoing bone marrow transplantation. JAMA."/>
  <result pre="and recurrent genital herpes. Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir treatment of herpes" exact="zoster" post="infections: use in children undergoing bone marrow transplantation. JAMA."/>
  <result pre="transplantation. JAMA. 1982;247:2132-21357038177 4.GuptaRWarrenTWaldAGenital herpes. Lancet. 2007;370:2127-213718156035 5.ReichmanRCBadgerGJMertzGJet al.Treatment of" exact="recurrent" post="genital herpes simplex infections with oral acyclovir: a controlled"/>
  <result pre="JAMA. 1982;247:2132-21357038177 4.GuptaRWarrenTWaldAGenital herpes. Lancet. 2007;370:2127-213718156035 5.ReichmanRCBadgerGJMertzGJet al.Treatment of recurrent" exact="genital herpes" post="simplex infections with oral acyclovir: a controlled trial. JAMA."/>
  <result pre="1982;247:2132-21357038177 4.GuptaRWarrenTWaldAGenital herpes. Lancet. 2007;370:2127-213718156035 5.ReichmanRCBadgerGJMertzGJet al.Treatment of recurrent genital" exact="herpes" post="simplex infections with oral acyclovir: a controlled trial. JAMA."/>
  <result pre="herpes. Lancet. 2007;370:2127-213718156035 5.ReichmanRCBadgerGJMertzGJet al.Treatment of recurrent genital herpes simplex" exact="infections" post="with oral acyclovir: a controlled trial. JAMA. 1984;251:2103-21076368877 6.LubyJPGnannJWJrAlexanderWJet"/>
  <result pre="JAMA. 1984;251:2103-21076368877 6.LubyJPGnannJWJrAlexanderWJet al.A collaborative study of patient-initiated treatment of" exact="recurrent" post="genital herpes with topical acyclovir or placebo. J Infect"/>
  <result pre="1984;251:2103-21076368877 6.LubyJPGnannJWJrAlexanderWJet al.A collaborative study of patient-initiated treatment of recurrent" exact="genital herpes" post="with topical acyclovir or placebo. J Infect Dis. 1984;150:1-66086765"/>
  <result pre="6.LubyJPGnannJWJrAlexanderWJet al.A collaborative study of patient-initiated treatment of recurrent genital" exact="herpes" post="with topical acyclovir or placebo. J Infect Dis. 1984;150:1-66086765"/>
  <result pre="acyclovir or placebo. J Infect Dis. 1984;150:1-66086765 7.CernikCGallinaKBrodellRTThe treatment of" exact="herpes" post="simplex infections: an evidence-based review. Arch Intern Med. 2008;168:1137-114418541820"/>
  <result pre="an evidence-based review. Arch Intern Med. 2008;168:1137-114418541820 8.ZuckermanRWaldAHerpes simplex virus" exact="infections" post="in solid organ transplant recipients. Am J Transplant. 2009;9(suppl"/>
  <result pre="herpesvirus infections. J Antimicrob Chemother. 1993;32(suppl A):121-1328407694 10.ValenciaIMilesDKMelvinJet al.Relapse of" exact="herpes" post="encephalitis after acyclovir therapy: report of two new cases"/>
  <result pre="infections. J Antimicrob Chemother. 1993;32(suppl A):121-1328407694 10.ValenciaIMilesDKMelvinJet al.Relapse of herpes" exact="encephalitis" post="after acyclovir therapy: report of two new cases and"/>
  <result pre="review of the literature. Neuropediatrics. 2004;35:371-37615627947 11.BalfourHHJrKellyJMSuarezCSet al.Acyclovir treatment of" exact="varicella" post="in otherwise healthy children. J Pediatr. 1990;116:633-6392156984 12.WallaceMRBowlerWAMurrayNBBrodineSKOldfieldECIIITreatment of"/>
  <result pre="varicella in otherwise healthy children. J Pediatr. 1990;116:633-6392156984 12.WallaceMRBowlerWAMurrayNBBrodineSKOldfieldECIIITreatment of" exact="adult" post="varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann"/>
  <result pre="in otherwise healthy children. J Pediatr. 1990;116:633-6392156984 12.WallaceMRBowlerWAMurrayNBBrodineSKOldfieldECIIITreatment of adult" exact="varicella" post="with oral acyclovir: a randomized, placebo-controlled trial. Ann Intern"/>
  <result pre="1992;117:358-3631323943 13.WoodMJKayRDworkinRHSoongSJWhitleyRJOral acyclovir therapy accelerates pain resolution in patients with" exact="herpes" post="zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis."/>
  <result pre="15.BeanBAeppliDAdverse effects of high-dose intravenous acyclovir in ambulatory patients with" exact="acute" post="herpes zoster. J Infect Dis. 1985;151:362-3653881542 16.PerazellaMACrystal-induced acute renal"/>
  <result pre="effects of high-dose intravenous acyclovir in ambulatory patients with acute" exact="herpes zoster." post="J Infect Dis. 1985;151:362-3653881542 16.PerazellaMACrystal-induced acute renal failure. Am"/>
  <result pre="patients with acute herpes zoster. J Infect Dis. 1985;151:362-3653881542 16.PerazellaMACrystal-induced" exact="acute" post="renal failure. Am J Med. 1999;106:459-46510225250 17.HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe aciclovir metabolite"/>
  <result pre="with acute herpes zoster. J Infect Dis. 1985;151:362-3653881542 16.PerazellaMACrystal-induced acute" exact="renal failure." post="Am J Med. 1999;106:459-46510225250 17.HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe aciclovir metabolite CMMG is"/>
  <result pre="haemopoiesis due to acyclovir. Lancet. 1983;1:242-2436130274 22.Danve-SzatanekCAymardMThouvenotDet al.Surveillance network for" exact="herpes" post="simplex virus resistance to antiviral drugs: 3-year follow-up. J"/>
  <result pre="2003;16:114-12812525428 24.MalvyDTreilhaudMBoueeSet al.A retrospective, case-control study of acyclovir resistance in" exact="herpes" post="simplex virus. Clin Infect Dis. 2005;41:320-32616007528 25.SupertiFAmmendoliaMGMarchettiMNew advances in"/>
  <result pre="of BVDU (brivudin) as a therapeutic for the treatment of" exact="herpes zoster." post="Biochem Pharmacol. 2004;68:2301-231515548377 27.LeaAPBrysonHMCidofovir. Drugs. 1996;52:225-2308841740 28.LanierRTrostLTippinTet al.Development of"/>
  <result pre="Drugs. 1996;52:225-2308841740 28.LanierRTrostLTippinTet al.Development of CMX001 for the treatment of" exact="poxvirus infections." post="Viruses. 2010;2:2740-276221499452 29.WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects of cidofovir with"/>
  <result pre="1998;32:1181-11929825085 32.CherringtonJMFullerMDLamyPDet al.In vitro antiviral susceptibilities of isolates from cytomegalovirus" exact="retinitis" post="patients receiving first- or second-line cidofovir therapy: relationship to"/>
  <result pre="J Infect Dis. 1998;178:1821-18259815243 33.JabsDAEngerCFormanMDunnJP; collab: The Cytomegalovirus Retinitis and" exact="Viral" post="Resistance Study GroupIncidence of foscarnet resistance and cidofovir resistance"/>
  <result pre="Infect Dis. 1998;178:1821-18259815243 33.JabsDAEngerCFormanMDunnJP; collab: The Cytomegalovirus Retinitis and Viral" exact="Resistance" post="Study GroupIncidence of foscarnet resistance and cidofovir resistance in"/>
  <result pre="in immunocompromised patients. Curr Opin Investig Drugs. 2002;3:1561-1566 35.ChaSJohnstonLNatkunamYBrownJTreatment of" exact="verruca" post="vulgaris with topical cidofovir in an immunocompromised patient: a"/>
  <result pre="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia," exact="herpes" post="simplex and its potential use in smallpox. Dermatol Clin."/>
  <result pre="Clin. 2003;21:301-30912757253 38.LalezariJPDrewWLGlutzerEet al.Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous" exact="infection" post="with herpes simplex virus in a patient with AIDS."/>
  <result pre="38.LalezariJPDrewWLGlutzerEet al.Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with" exact="herpes" post="simplex virus in a patient with AIDS. J Infect"/>
  <result pre="with AIDS. J Infect Dis. 1994;170:570-5728077713 39.BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant" exact="herpes" post="simplex stomatitis with intravenous cidofovir in a child. Pediatr"/>
  <result pre="J Infect Dis. 1994;170:570-5728077713 39.BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex" exact="stomatitis" post="with intravenous cidofovir in a child. Pediatr Infect Dis"/>
  <result pre="Pediatr Infect Dis J. 2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant" exact="herpes" post="simplex type 2 infection with cidofovir in an AIDS"/>
  <result pre="Dis J. 2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant herpes simplex" exact="type 2" post="infection with cidofovir in an AIDS patient. Br J"/>
  <result pre="2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant herpes simplex type 2" exact="infection" post="with cidofovir in an AIDS patient. Br J Dermatol."/>
  <result pre="series. AIDS. 2006;20:791-79316514320 42.MarraCMRajicicNBarkerDEet al.A pilot study of cidofovir for" exact="progressive multifocal leukoencephalopathy" post="in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of progressive multifocal"/>
  <result pre="2006;20:791-79316514320 42.MarraCMRajicicNBarkerDEet al.A pilot study of cidofovir for progressive multifocal" exact="leukoencephalopathy" post="in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of progressive multifocal"/>
  <result pre="progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of" exact="progressive multifocal leukoencephalopathy" post="in a patient receiving highly active antiretroviral therapy. Mayo"/>
  <result pre="leukoencephalopathy in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir treatment of progressive multifocal" exact="leukoencephalopathy" post="in a patient receiving highly active antiretroviral therapy. Mayo"/>
  <result pre="antiretroviral therapy. Mayo Clin Proc. 2001;76:1171-117511702907 44.Segarra-NewnhamMVodoloKMUse of cidofovir in" exact="progressive multifocal leukoencephalopathy." post="Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement of progressive multifocal leukoencephalopathy"/>
  <result pre="in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement of" exact="progressive multifocal leukoencephalopathy" post="after cidofovir therapy in a patient with a destructive"/>
  <result pre="multifocal leukoencephalopathy. Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement of progressive multifocal" exact="leukoencephalopathy" post="after cidofovir therapy in a patient with a destructive"/>
  <result pre="study. Clin Infect Dis. 2009;49:233-24019522651 47.KottkeMDParkerSRIntravenous cidofovir-induced resolution of disfiguring" exact="cutaneous" post="human papillomavirus infection. J Am Acad Dermatol. 2006;55:533-53616908370 48.KazoryASingapuriSWadhwaAEjazAASimultaneous"/>
  <result pre="papillomavirus infection. J Am Acad Dermatol. 2006;55:533-53616908370 48.KazoryASingapuriSWadhwaAEjazAASimultaneous development of" exact="Fanconi syndrome" post="and acute renal failure associated with cidofovir. J Antimicrob"/>
  <result pre="infection. J Am Acad Dermatol. 2006;55:533-53616908370 48.KazoryASingapuriSWadhwaAEjazAASimultaneous development of Fanconi" exact="syndrome" post="and acute renal failure associated with cidofovir. J Antimicrob"/>
  <result pre="Am Acad Dermatol. 2006;55:533-53616908370 48.KazoryASingapuriSWadhwaAEjazAASimultaneous development of Fanconi syndrome and" exact="acute" post="renal failure associated with cidofovir. J Antimicrob Chemother. 2007;60:193-19417496056"/>
  <result pre="Acad Dermatol. 2006;55:533-53616908370 48.KazoryASingapuriSWadhwaAEjazAASimultaneous development of Fanconi syndrome and acute" exact="renal failure" post="associated with cidofovir. J Antimicrob Chemother. 2007;60:193-19417496056 49.AmbatiJWynneKBAngerameMCRobinsonMRAnterior uveitis"/>
  <result pre="renal failure associated with cidofovir. J Antimicrob Chemother. 2007;60:193-19417496056 49.AmbatiJWynneKBAngerameMCRobinsonMRAnterior" exact="uveitis" post="associated with intravenous cidofovir use in patients with cytomegalovirus"/>
  <result pre="Pharmacokinet. 1996;31:1-88827396 52.FaroSA review of famciclovir in the management of" exact="genital herpes." post="Infect Dis Obstet Gynecol. 1998;6:38-439678146 53.ChackoMWeinbergJMFamciclovir for cutaneous herpesvirus"/>
  <result pre="of genital herpes. Infect Dis Obstet Gynecol. 1998;6:38-439678146 53.ChackoMWeinbergJMFamciclovir for" exact="cutaneous" post="herpesvirus infections: an update and review of new single-day"/>
  <result pre="dosing indications. Cutis. 2007;80:77-8117725069 54.SaltzmanRJurewiczRBoonRSafety of famciclovir in patients with" exact="herpes zoster" post="and genital herpes. Antimicrob Agents Chemother. 1994;38:2454-24577840587 55.GrilloneLRLanzRFomivirsen. Drugs"/>
  <result pre="indications. Cutis. 2007;80:77-8117725069 54.SaltzmanRJurewiczRBoonRSafety of famciclovir in patients with herpes" exact="zoster" post="and genital herpes. Antimicrob Agents Chemother. 1994;38:2454-24577840587 55.GrilloneLRLanzRFomivirsen. Drugs"/>
  <result pre="2007;80:77-8117725069 54.SaltzmanRJurewiczRBoonRSafety of famciclovir in patients with herpes zoster and" exact="genital herpes." post="Antimicrob Agents Chemother. 1994;38:2454-24577840587 55.GrilloneLRLanzRFomivirsen. Drugs Today (Barc). 2001;37:245-25512768225"/>
  <result pre="clinical trial of intravitreous fomivirsen for treatment of newly diagnosed" exact="peripheral" post="cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol."/>
  <result pre="of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus" exact="retinitis" post="in patients with AIDS. Am J Ophthalmol. 2002;133:467-47411931780 57.HighleymanLFomivirsen."/>
  <result pre="59.BalfourHHJrFletcherCVEriceAet al.Effect of foscarnet on quantities of cytomegalovirus and human" exact="immunodeficiency" post="virus in blood of persons with AIDS. Antimicrob Agents"/>
  <result pre="dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus" exact="retinitis" post="in AIDS. J Infect Dis. 1993;168:444-4488393058 63.BeaufilsHDerayGKatlamaCet al.Foscarnet and"/>
  <result pre="prevention of CMV infections. J Clin Virol. 2000;16:25-4010680738 66.FrankKBChiouJFChengYCInteraction of" exact="herpes" post="simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol"/>
  <result pre="Biol Chem. 1984;259:1566-15696319402 67.RazonableRRPayaCVThe impact of human herpesvirus-6 and -7" exact="infection" post="on the outcome of liver transplantation. Liver Transpl. 2002;8:651-65812149755"/>
  <result pre="impact of human herpesvirus-6 and -7 infection on the outcome" exact="of liver" post="transplantation. Liver Transpl. 2002;8:651-65812149755 68.SpectorSAWeingeistTPollardRBet al.; collab: AIDS Clinical"/>
  <result pre="GroupA randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus" exact="peripheral" post="retinitis in patients with AIDS. J Infect Dis. 1993;168:557-5638394858"/>
  <result pre="randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral" exact="retinitis" post="in patients with AIDS. J Infect Dis. 1993;168:557-5638394858 69.DrewWLIvesDLalezariJPet"/>
  <result pre="Oral Ganciclovir Study GroupOral ganciclovir as maintenance treatment for cytomegalovirus" exact="retinitis" post="in patients with AIDS. N Engl J Med. 1995;333:615-6207637721"/>
  <result pre="and safety of oral ganciclovir in the prevention of cytomegalovirus" exact="disease" post="in liver-transplant recipients [published correction appears in Lancet. 1998;351(9100):454]."/>
  <result pre="2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet al.Profiling penciclovir susceptibility and prevalence of resistance of" exact="herpes" post="simplex virus isolates across eleven clinical trials. Arch Virol."/>
  <result pre="Topical Penciclovir Collaborative Study GroupPenciclovir cream for the treatment of" exact="herpes" post="simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA."/>
  <result pre="placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of" exact="recurrent" post="herpes genitalis. Arch Intern Med. 1996;156:1729-17358694673 77.PergamSALimayeAPVaricella zoster virus"/>
  <result pre="dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent" exact="herpes" post="genitalis. Arch Intern Med. 1996;156:1729-17358694673 77.PergamSALimayeAPVaricella zoster virus (VZV)"/>
  <result pre="treatment of recurrent herpes genitalis. Arch Intern Med. 1996;156:1729-17358694673 77.PergamSALimayeAPVaricella" exact="zoster" post="virus (VZV) in solid organ transplant recipients. Am J"/>
  <result pre="Cytomegalovirus Prophylaxis Transplantation Study GroupValacyclovir for the prevention of cytomegalovirus" exact="disease" post="after renal transplantation. N Engl J Med. 1999;340:1462-147010320384 79.RazonableRRPayaCVValganciclovir"/>
  <result pre="Med. 1999;340:1462-147010320384 79.RazonableRRPayaCVValganciclovir for the prevention and treatment of cytomegalovirus" exact="disease" post="in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004;2:27-4115482169"/>
  <result pre="safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus" exact="disease" post="in solid organ transplant recipients. Am J Transplant. 2004;4:611-62015023154"/>
  <result pre="85.KhouryJAStorchGABohlDLet al.Prophylactic versus preemptive oral valganciclovir for the management of" exact="cytomegalovirus infection" post="in adult renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548"/>
  <result pre="al.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus" exact="infection" post="in adult renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548"/>
  <result pre="preemptive oral valganciclovir for the management of cytomegalovirus infection in" exact="adult" post="renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548 86.SnydmanDRUse of"/>
  <result pre="2006;6:2134-214316780548 86.SnydmanDRUse of valganciclovir for prevention and treatment of cytomegalovirus" exact="disease" post="[editorial]. Clin Infect Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet al.Oral valganciclovir leads"/>
  <result pre="cell transplantation. Blood. 2006;107:3002-300816352807 88.LenOGavaldaJAguadoJMet al.Valganciclovir as treatment for cytomegalovirus" exact="disease" post="in solid organ transplant recipients. Clin Infect Dis. 2008;46:20-2718171208"/>
  <result pre="is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus" exact="disease" post="in solid organ transplant recipients. Am J Transplant. 2007;7:2106-211317640310"/>
  <result pre="organ transplant recipients. Am J Transplant. 2007;7:2106-211317640310 90.WilhelmusKRTherapeutic interventions for" exact="herpes" post="simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2008;CD00289818254009"/>
  <result pre="Am J Transplant. 2007;7:2106-211317640310 90.WilhelmusKRTherapeutic interventions for herpes simplex virus" exact="epithelial" post="keratitis. Cochrane Database Syst Rev. 2008;CD00289818254009 91.De ClercqEAntiviral drugs"/>
  <result pre="of the clinical effectiveness of oseltamivir and zanamivir against influenza" exact="virus infection" post="in children. Clin Infect Dis. 2008;47:339-34518582202 100.KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic review: safety"/>
  <result pre="the clinical effectiveness of oseltamivir and zanamivir against influenza virus" exact="infection" post="in children. Clin Infect Dis. 2008;47:339-34518582202 100.KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic review: safety"/>
  <result pre="Dis. 2003;23(suppl 1):19-2212934164 112.WongDKCheungAMO’RourkeKNaylorCDDetskyASHeathcoteJEffect of alpha-interferon treatment in patients with" exact="hepatitis" post="B e antigen-positive chronic hepatitis B: a meta-analysis. Ann"/>
  <result pre="of alpha-interferon treatment in patients with hepatitis B e antigen-positive" exact="chronic hepatitis" post="B: a meta-analysis. Ann Intern Med. 1993;119:312-3238328741 113.HariaMBenfieldPInterferon-alpha-2a: a"/>
  <result pre="alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic" exact="hepatitis" post="B: a meta-analysis. Ann Intern Med. 1993;119:312-3238328741 113.HariaMBenfieldPInterferon-alpha-2a: a"/>
  <result pre="its pharmacological properties and therapeutic use in the management of" exact="viral hepatitis." post="Drugs. 1995;50:873-8968586031 114.LokASMcMahonBJChronic hepatitis B: update 2009. Hepatology. 2009;50:661-66219714720"/>
  <result pre="use in the management of viral hepatitis. Drugs. 1995;50:873-8968586031 114.LokASMcMahonBJChronic" exact="hepatitis" post="B: update 2009. Hepatology. 2009;50:661-66219714720 115.MarcellinPAsselahTBoyerNTreatment of chronic hepatitis"/>
  <result pre="1995;50:873-8968586031 114.LokASMcMahonBJChronic hepatitis B: update 2009. Hepatology. 2009;50:661-66219714720 115.MarcellinPAsselahTBoyerNTreatment of" exact="chronic hepatitis" post="B. J Viral Hepat. 2005;12:333-34515985003 116.LauGKPiratvisuthTLuoKXet al.Peginterferon alfa-2a, lamivudine,"/>
  <result pre="114.LokASMcMahonBJChronic hepatitis B: update 2009. Hepatology. 2009;50:661-66219714720 115.MarcellinPAsselahTBoyerNTreatment of chronic" exact="hepatitis" post="B. J Viral Hepat. 2005;12:333-34515985003 116.LauGKPiratvisuthTLuoKXet al.Peginterferon alfa-2a, lamivudine,"/>
  <result pre="update 2009. Hepatology. 2009;50:661-66219714720 115.MarcellinPAsselahTBoyerNTreatment of chronic hepatitis B. J" exact="Viral" post="Hepat. 2005;12:333-34515985003 116.LauGKPiratvisuthTLuoKXet al.Peginterferon alfa-2a, lamivudine, and the combination"/>
  <result pre="2005;12:333-34515985003 116.LauGKPiratvisuthTLuoKXet al.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive" exact="chronic hepatitis" post="B. N Engl J Med. 2005;352:2682-269515987917 117.MarcellinPLauGKBoninoFet al.Peginterferon alfa-2a"/>
  <result pre="116.LauGKPiratvisuthTLuoKXet al.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic" exact="hepatitis" post="B. N Engl J Med. 2005;352:2682-269515987917 117.MarcellinPLauGKBoninoFet al.Peginterferon alfa-2a"/>
  <result pre="alone, and the two in combination in patients with HBeAg-negative" exact="chronic hepatitis" post="B. N Engl J Med. 2004;351:1206-121715371578 118.JanssenHLvan ZonneveldMSenturkHet al.Pegylated"/>
  <result pre="and the two in combination in patients with HBeAg-negative chronic" exact="hepatitis" post="B. N Engl J Med. 2004;351:1206-121715371578 118.JanssenHLvan ZonneveldMSenturkHet al.Pegylated"/>
  <result pre="Interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive" exact="chronic hepatitis" post="B: a randomised trial. Lancet. 2005;365:123-12915639293 119.FarciPMandasACoianaAet al.Treatment of"/>
  <result pre="alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic" exact="hepatitis" post="B: a randomised trial. Lancet. 2005;365:123-12915639293 119.FarciPMandasACoianaAet al.Treatment of"/>
  <result pre="hepatitis B: a randomised trial. Lancet. 2005;365:123-12915639293 119.FarciPMandasACoianaAet al.Treatment of" exact="chronic hepatitis" post="D with interferon alfa-2a. N Engl J Med. 1994;330:88-948259188"/>
  <result pre="B: a randomised trial. Lancet. 2005;365:123-12915639293 119.FarciPMandasACoianaAet al.Treatment of chronic" exact="hepatitis" post="D with interferon alfa-2a. N Engl J Med. 1994;330:88-948259188"/>
  <result pre="Med. 1994;330:88-948259188 120.FarciPRoskamsTChessaLet al.Long-term benefit of interferon alpha therapy of" exact="chronic hepatitis" post="D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-174915188169 121.SorianoVPuotiMBonaciniMet"/>
  <result pre="1994;330:88-948259188 120.FarciPRoskamsTChessaLet al.Long-term benefit of interferon alpha therapy of chronic" exact="hepatitis" post="D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-174915188169 121.SorianoVPuotiMBonaciniMet"/>
  <result pre="interferon alpha therapy of chronic hepatitis D: regression of advanced" exact="hepatic fibrosis." post="Gastroenterology. 2004;126:1740-174915188169 121.SorianoVPuotiMBonaciniMet al.Care of patients with chronic hepatitis"/>
  <result pre="advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-174915188169 121.SorianoVPuotiMBonaciniMet al.Care of patients with" exact="chronic hepatitis" post="B and HIV co-infection: recommendations from an HIV-HBV International"/>
  <result pre="hepatic fibrosis. Gastroenterology. 2004;126:1740-174915188169 121.SorianoVPuotiMBonaciniMet al.Care of patients with chronic" exact="hepatitis" post="B and HIV co-infection: recommendations from an HIV-HBV International"/>
  <result pre="of the first European Consensus Conference on the treatment of" exact="chronic hepatitis" post="B and C in HIV co-infected patients. J Hepatol."/>
  <result pre="the first European Consensus Conference on the treatment of chronic" exact="hepatitis" post="B and C in HIV co-infected patients. J Hepatol."/>
  <result pre="123.PoynardTLeroyVCohardMet al.Meta-analysis of interferon randomized trials in the treatment of" exact="viral hepatitis" post="C: effects of dose and duration. Hepatology. 1996;24:778-7898855176 124.ZeuzemSFeinmanSVRasenackJet"/>
  <result pre="al.Meta-analysis of interferon randomized trials in the treatment of viral" exact="hepatitis" post="C: effects of dose and duration. Hepatology. 1996;24:778-7898855176 124.ZeuzemSFeinmanSVRasenackJet"/>
  <result pre="and duration. Hepatology. 1996;24:778-7898855176 124.ZeuzemSFeinmanSVRasenackJet al.Peginterferon alfa-2a in patients with" exact="chronic hepatitis" post="C. N Engl J Med. 2000;343:1666-167211106715 125.PerryCMJarvisBPeginterferon-alpha-2a (40 kD):"/>
  <result pre="duration. Hepatology. 1996;24:778-7898855176 124.ZeuzemSFeinmanSVRasenackJet al.Peginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C. N Engl J Med. 2000;343:1666-167211106715 125.PerryCMJarvisBPeginterferon-alpha-2a (40 kD):"/>
  <result pre="kD): a review of its use in the management of" exact="chronic hepatitis" post="C. Drugs. 2001;61:2263-228811772139 126.HeathcoteEJShiffmanMLCooksleyWGet al.Peginterferon alfa-2a in patients with"/>
  <result pre="a review of its use in the management of chronic" exact="hepatitis" post="C. Drugs. 2001;61:2263-228811772139 126.HeathcoteEJShiffmanMLCooksleyWGet al.Peginterferon alfa-2a in patients with"/>
  <result pre="hepatitis C. Drugs. 2001;61:2263-228811772139 126.HeathcoteEJShiffmanMLCooksleyWGet al.Peginterferon alfa-2a in patients with" exact="chronic hepatitis" post="C and cirrhosis. N Engl J Med. 2000;343:1673-168011106716 127.BrokJGluudLLGluudCRibavirin"/>
  <result pre="C. Drugs. 2001;61:2263-228811772139 126.HeathcoteEJShiffmanMLCooksleyWGet al.Peginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C and cirrhosis. N Engl J Med. 2000;343:1673-168011106716 127.BrokJGluudLLGluudCRibavirin"/>
  <result pre="Engl J Med. 2000;343:1673-168011106716 127.BrokJGluudLLGluudCRibavirin plus interferon versus interferon for" exact="chronic hepatitis" post="C. Cochrane Database Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a"/>
  <result pre="J Med. 2000;343:1673-168011106716 127.BrokJGluudLLGluudCRibavirin plus interferon versus interferon for chronic" exact="hepatitis" post="C. Cochrane Database Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a"/>
  <result pre="Database Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for" exact="chronic hepatitis" post="C virus infection. N Engl J Med. 2002;347:975-98212324553 129.MannsMPMcHutchisonJGGordonSCet"/>
  <result pre="Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection. N Engl J Med. 2002;347:975-98212324553 129.MannsMPMcHutchisonJGGordonSCet"/>
  <result pre="2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C" exact="virus infection." post="N Engl J Med. 2002;347:975-98212324553 129.MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus"/>
  <result pre="compared with interferon alfa-2b plus ribavirin for initial treatment of" exact="chronic hepatitis" post="C: a randomised trial. Lancet. 2001;358:958-96511583749 130.GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and"/>
  <result pre="with interferon alfa-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="C: a randomised trial. Lancet. 2001;358:958-96511583749 130.GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and"/>
  <result pre="a randomised trial. Lancet. 2001;358:958-96511583749 130.GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of" exact="hepatitis" post="C: an update. Hepatology. 2009;49:1335-137419330875 131.CarratFBani-SadrFPolSet al.Pegylated interferon alfa-2b"/>
  <result pre="al.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for" exact="chronic hepatitis" post="C in HIV-infected patients: a randomized controlled trial. JAMA."/>
  <result pre="interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic" exact="hepatitis" post="C in HIV-infected patients: a randomized controlled trial. JAMA."/>
  <result pre="controlled trial. JAMA. 2004;292:2839-284815598915 132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus ribavirin for" exact="chronic hepatitis" post="C virus infection in HIV-infected patients. N Engl J"/>
  <result pre="trial. JAMA. 2004;292:2839-284815598915 132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection in HIV-infected patients. N Engl J"/>
  <result pre="2004;292:2839-284815598915 132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C" exact="virus infection" post="in HIV-infected patients. N Engl J Med. 2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet"/>
  <result pre="132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus" exact="infection" post="in HIV-infected patients. N Engl J Med. 2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet"/>
  <result pre="al.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for" exact="chronic hepatitis" post="C in HIV-coinfected persons. N Engl J Med. 2004;351:451-45915282352"/>
  <result pre="Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C in HIV-coinfected persons. N Engl J Med. 2004;351:451-45915282352"/>
  <result pre="HIV-coinfected persons. N Engl J Med. 2004;351:451-45915282352 134.JaeckelECornbergMWedemeyerHet al.Treatment of" exact="acute hepatitis" post="C with interferon alfa-2b. N Engl J Med. 2001;345:1452-145711794193"/>
  <result pre="persons. N Engl J Med. 2004;351:451-45915282352 134.JaeckelECornbergMWedemeyerHet al.Treatment of acute" exact="hepatitis" post="C with interferon alfa-2b. N Engl J Med. 2001;345:1452-145711794193"/>
  <result pre="a 24-week course of PEG-interferon alpha-2b monotherapy in patients with" exact="acute hepatitis" post="C after failure of spontaneous clearance. J Hepatol. 2005;42:329-33315710214"/>
  <result pre="24-week course of PEG-interferon alpha-2b monotherapy in patients with acute" exact="hepatitis" post="C after failure of spontaneous clearance. J Hepatol. 2005;42:329-33315710214"/>
  <result pre="of spontaneous clearance. J Hepatol. 2005;42:329-33315710214 136.EronLJJudsonFTuckerSet al.Interferon therapy for" exact="condylomata acuminata." post="N Engl J Med. 1986;315:1059-10643531860 137.LeungDTSacksSLCurrent recommendations for the"/>
  <result pre="Engl J Med. 1986;315:1059-10643531860 137.LeungDTSacksSLCurrent recommendations for the treatment of" exact="genital herpes." post="Drugs. 2000;60:1329-135211152015 138.HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in HIV-associated progressive multifocal"/>
  <result pre="of genital herpes. Drugs. 2000;60:1329-135211152015 138.HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in HIV-associated" exact="progressive multifocal leukoencephalopathy" post="treated with alpha-interferon: an observational study. J Neurovirol. 1998;4:324-3329639075"/>
  <result pre="herpes. Drugs. 2000;60:1329-135211152015 138.HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in HIV-associated progressive multifocal" exact="leukoencephalopathy" post="treated with alpha-interferon: an observational study. J Neurovirol. 1998;4:324-3329639075"/>
  <result pre="139.GeschwindMDSkolaskyRIRoyalWSMcArthurJCThe relative contributions of HAART and alpha-interferon for therapy of" exact="progressive multifocal leukoencephalopathy" post="in AIDS. J Neurovirol. 2001;7:353-35711517416 140.RenaultPFHoofnagleJHParkYet al.Psychiatric complications of"/>
  <result pre="contributions of HAART and alpha-interferon for therapy of progressive multifocal" exact="leukoencephalopathy" post="in AIDS. J Neurovirol. 2001;7:353-35711517416 140.RenaultPFHoofnagleJHParkYet al.Psychiatric complications of"/>
  <result pre="alfa therapy. Arch Intern Med. 1987;147:1577-15803307672 141.DieperinkEWillenbringMHoSBNeuropsychiatric symptoms associated with" exact="hepatitis" post="C and interferon19 alpha: a review. Am J Psychiatry."/>
  <result pre="interferon19 alpha: a review. Am J Psychiatry. 2000;157:867-87610831463 142.MidturiJSierra-HoffmanMHurleyDWinnRBeissnerRCarpenterJSpectrum of" exact="pulmonary" post="toxicity associated with the use of interferon therapy for"/>
  <result pre="pulmonary toxicity associated with the use of interferon therapy for" exact="hepatitis" post="C: case report and review of the literature. Clin"/>
  <result pre="of the literature. Clin Infect Dis. 2004;39:1724-172915578378 143.LevensonJLFallonHJFluoxetine treatment of" exact="depression" post="caused by interferon-alpha. Am J Gastroenterol. 1993;88:760-7618480744 144.MusselmanDLLawsonDHGumnickJFet al.Paroxetine"/>
  <result pre="Am J Gastroenterol. 1993;88:760-7618480744 144.MusselmanDLLawsonDHGumnickJFet al.Paroxetine for the prevention of" exact="depression" post="induced by high-dose interferon alfa. N Engl J Med."/>
  <result pre="145.DurandJMKaplanskiGPortalIScheinerCBerlandYSoubeyrandJLiver failure due to recombinant alpha interferon. Lancet. 1991;338:1268-12691682660 146.AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute" exact="interstitial nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
  <result pre="failure due to recombinant alpha interferon. Lancet. 1991;338:1268-12691682660 146.AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial" exact="nephritis" post="with the nephrotic syndrome following recombinant leukocyte a interferon"/>
  <result pre="recombinant alpha interferon. Lancet. 1991;338:1268-12691682660 146.AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial nephritis with the" exact="nephrotic syndrome" post="following recombinant leukocyte a interferon therapy for mycosis fungoides."/>
  <result pre="alpha interferon. Lancet. 1991;338:1268-12691682660 146.AverbuchSDAustinHAIIISherwinSAAntonovychTBunnPAJrLongoDLAcute interstitial nephritis with the nephrotic" exact="syndrome" post="following recombinant leukocyte a interferon therapy for mycosis fungoides."/>
  <result pre="the nephrotic syndrome following recombinant leukocyte a interferon therapy for" exact="mycosis" post="fungoides. N Engl J Med. 1984;310:32-356689738 147.AgestaNZabalaRDiaz-PerezJLAlopecia areata during"/>
  <result pre="alpha-2b/ribavirin therapy. Dermatology. 2002;205:300-30112399683 148.WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of ribavirin in patients with" exact="hepatitis" post="C virus. Br J Clin Pharmacol. 2006;62:710-71417118126 149.KramerTHGaarGGRayCGMinnichLCopelandJGConnorJDHemodialysis clearance"/>
  <result pre="ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon plus ribavirin for" exact="chronic hepatitis" post="C in patients with human immunodeficiency virus. Am J"/>
  <result pre="molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon plus ribavirin for chronic" exact="hepatitis" post="C in patients with human immunodeficiency virus. Am J"/>
  <result pre="plus ribavirin for chronic hepatitis C in patients with human" exact="immunodeficiency" post="virus. Am J Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial"/>
  <result pre="with human immunodeficiency virus. Am J Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for" exact="respiratory" post="syncytial virus infection of the lower respiratory tract in"/>
  <result pre="immunodeficiency virus. Am J Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial" exact="virus infection" post="of the lower respiratory tract in infants and young"/>
  <result pre="virus. Am J Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial virus" exact="infection" post="of the lower respiratory tract in infants and young"/>
  <result pre="Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial virus infection of the" exact="lower" post="respiratory tract in infants and young children. Cochrane Database"/>
  <result pre="2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial virus infection of the lower" exact="respiratory" post="tract in infants and young children. Cochrane Database Syst"/>
  <result pre="153.PelaezALyonGMForceSDet al.Efficacy of oral ribavirin in lung transplant patients with" exact="respiratory" post="syncytial virus lower respiratory tract infection. J Heart Lung"/>
  <result pre="oral ribavirin in lung transplant patients with respiratory syncytial virus" exact="lower" post="respiratory tract infection. J Heart Lung Transplant. 2009;28:67-7119134533 154.KnowlesSRPhillipsEJDresserLMatukasLCommon"/>
  <result pre="ribavirin in lung transplant patients with respiratory syncytial virus lower" exact="respiratory" post="tract infection. J Heart Lung Transplant. 2009;28:67-7119134533 154.KnowlesSRPhillipsEJDresserLMatukasLCommon adverse"/>
  <result pre="patients with respiratory syncytial virus lower respiratory tract infection. J" exact="Heart" post="Lung Transplant. 2009;28:67-7119134533 154.KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the"/>
  <result pre="adverse events associated with the use of ribavirin for severe" exact="acute" post="respiratory syndrome in Canada. Clin Infect Dis. 2003;37:1139-114214523782 155.MullerMPDresserLRaboudJet"/>
  <result pre="events associated with the use of ribavirin for severe acute" exact="respiratory" post="syndrome in Canada. Clin Infect Dis. 2003;37:1139-114214523782 155.MullerMPDresserLRaboudJet al.Adverse"/>
  <result pre="associated with the use of ribavirin for severe acute respiratory" exact="syndrome" post="in Canada. Clin Infect Dis. 2003;37:1139-114214523782 155.MullerMPDresserLRaboudJet al.Adverse events"/>
  <result pre="with high-dose ribavirin: evidence from the Toronto outbreak of severe" exact="acute" post="respiratory syndrome. Pharmacotherapy. 2007;27:494-50317381375 156.McJunkinJEKhanRde los ReyesECet al.Treatment of"/>
  <result pre="high-dose ribavirin: evidence from the Toronto outbreak of severe acute" exact="respiratory" post="syndrome. Pharmacotherapy. 2007;27:494-50317381375 156.McJunkinJEKhanRde los ReyesECet al.Treatment of severe"/>
  <result pre="respiratory syndrome. Pharmacotherapy. 2007;27:494-50317381375 156.McJunkinJEKhanRde los ReyesECet al.Treatment of severe" exact="La Crosse encephalitis" post="with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics."/>
  <result pre="Pharmacotherapy. 2007;27:494-50317381375 156.McJunkinJEKhanRde los ReyesECet al.Treatment of severe La Crosse" exact="encephalitis" post="with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics."/>
  <result pre="following diagnosis by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment of" exact="acute" post="Nipah encephalitis with ribavirin. Ann Neurol. 2001;49:810-81311409437 158.McCormickJBKingIJWebbPAet al.Lassa"/>
  <result pre="diagnosis by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment of acute" exact="Nipah encephalitis" post="with ribavirin. Ann Neurol. 2001;49:810-81311409437 158.McCormickJBKingIJWebbPAet al.Lassa fever: effective"/>
  <result pre="by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment of acute Nipah" exact="encephalitis" post="with ribavirin. Ann Neurol. 2001;49:810-81311409437 158.McCormickJBKingIJWebbPAet al.Lassa fever: effective"/>
  <result pre="double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of" exact="hemorrhagic fever with renal syndrome." post="J Infect Dis. 1991;164:1119-11271683355 160.Fisher-HochSPKhanJARehmanSMirzaSKhurshidMMcCormickJBCrimean Congo-haemorrhagic fever treated with"/>
  <result pre="1995;346:472-4757637481 161.MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral ribavirin in the treatment of" exact="Crimean-Congo hemorrhagic fever" post="in Iran. Clin Infect Dis. 2003;36:1613-161812802764 162.KilgorePEKsiazekTGRollinPEet al.Treatment of"/>
  <result pre="fever in Iran. Clin Infect Dis. 2003;36:1613-161812802764 162.KilgorePEKsiazekTGRollinPEet al.Treatment of" exact="Bolivian hemorrhagic fever" post="with intravenous ribavirin. Clin Infect Dis. 1997;24:718-7229145749 163.ProchodaKMostowSRGreenbergKHantavirus-associated acute"/>
  <result pre="hemorrhagic fever with intravenous ribavirin. Clin Infect Dis. 1997;24:718-7229145749 163.ProchodaKMostowSRGreenbergKHantavirus-associated" exact="acute" post="respiratory failure. N Engl J Med. 1993;329:17448232482 164.DandoTPloskerGAdefovir dipivoxil:"/>
  <result pre="fever with intravenous ribavirin. Clin Infect Dis. 1997;24:718-7229145749 163.ProchodaKMostowSRGreenbergKHantavirus-associated acute" exact="respiratory" post="failure. N Engl J Med. 1993;329:17448232482 164.DandoTPloskerGAdefovir dipivoxil: a"/>
  <result pre="Med. 1993;329:17448232482 164.DandoTPloskerGAdefovir dipivoxil: a review of its use in" exact="chronic hepatitis" post="B. Drugs. 2003;63:2215-223414498759 165.RivkinAMAdefovir dipivoxil in the treatment of"/>
  <result pre="1993;329:17448232482 164.DandoTPloskerGAdefovir dipivoxil: a review of its use in chronic" exact="hepatitis" post="B. Drugs. 2003;63:2215-223414498759 165.RivkinAMAdefovir dipivoxil in the treatment of"/>
  <result pre="hepatitis B. Drugs. 2003;63:2215-223414498759 165.RivkinAMAdefovir dipivoxil in the treatment of" exact="chronic hepatitis" post="B. Ann Pharmacother. 2004;38:625-63314990784 166.MarcellinPChangTTLimSGet al.Adefovir dipivoxil for the"/>
  <result pre="B. Drugs. 2003;63:2215-223414498759 165.RivkinAMAdefovir dipivoxil in the treatment of chronic" exact="hepatitis" post="B. Ann Pharmacother. 2004;38:625-63314990784 166.MarcellinPChangTTLimSGet al.Adefovir dipivoxil for the"/>
  <result pre="Ann Pharmacother. 2004;38:625-63314990784 166.MarcellinPChangTTLimSGet al.Adefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-positive chronic hepatitis B. N Engl J"/>
  <result pre="al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive" exact="chronic hepatitis" post="B. N Engl J Med. 2003;348:808-81612606735 167.HadziyannisSJTassopoulosNCHeathcoteEJet al.Adefovir dipivoxil"/>
  <result pre="dipivoxil for the treatment of hepatitis B e antigen-positive chronic" exact="hepatitis" post="B. N Engl J Med. 2003;348:808-81612606735 167.HadziyannisSJTassopoulosNCHeathcoteEJet al.Adefovir dipivoxil"/>
  <result pre="J Med. 2003;348:808-81612606735 167.HadziyannisSJTassopoulosNCHeathcoteEJet al.Adefovir dipivoxil for the treatment of" exact="hepatitis" post="B e antigen-negative chronic hepatitis B. N Engl J"/>
  <result pre="al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative" exact="chronic hepatitis" post="B. N Engl J Med. 2003;348:800-80712606734 168.HadziyannisSJTassopoulosNCHeathcoteEJet al.Long-term therapy"/>
  <result pre="dipivoxil for the treatment of hepatitis B e antigen-negative chronic" exact="hepatitis" post="B. N Engl J Med. 2003;348:800-80712606734 168.HadziyannisSJTassopoulosNCHeathcoteEJet al.Long-term therapy"/>
  <result pre="Med. 2003;348:800-80712606734 168.HadziyannisSJTassopoulosNCHeathcoteEJet al.Long-term therapy with adefovir dipivoxil for HBeAg-negative" exact="chronic hepatitis" post="B. N Engl J Med. 2005;352:2673-268115987916 169.DelaneyWEProgress in the"/>
  <result pre="2003;348:800-80712606734 168.HadziyannisSJTassopoulosNCHeathcoteEJet al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic" exact="hepatitis" post="B. N Engl J Med. 2005;352:2673-268115987916 169.DelaneyWEProgress in the"/>
  <result pre="N Engl J Med. 2005;352:2673-268115987916 169.DelaneyWEProgress in the treatment of" exact="chronic hepatitis" post="B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother."/>
  <result pre="Engl J Med. 2005;352:2673-268115987916 169.DelaneyWEProgress in the treatment of chronic" exact="hepatitis" post="B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother."/>
  <result pre="Chemother. 2007;59:827-83217332007 170.LimSGNgTMKungNet al.A double-blind placebo-controlled study of emtricitabine in" exact="chronic hepatitis" post="B. Arch Intern Med. 2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir: a new nucleoside"/>
  <result pre="2007;59:827-83217332007 170.LimSGNgTMKungNet al.A double-blind placebo-controlled study of emtricitabine in chronic" exact="hepatitis" post="B. Arch Intern Med. 2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir: a new nucleoside"/>
  <result pre="2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir: a new nucleoside analog for the treatment of" exact="chronic hepatitis" post="B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the treatment of"/>
  <result pre="171.SimsKAWoodlandAMEntecavir: a new nucleoside analog for the treatment of chronic" exact="hepatitis" post="B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the treatment of"/>
  <result pre="hepatitis B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the treatment of" exact="chronic hepatitis" post="B virus infection. Clin Ther. 2006;28:184-20316678641 173.ScottLJKeatingGMEntecavir: a review"/>
  <result pre="B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the treatment of chronic" exact="hepatitis" post="B virus infection. Clin Ther. 2006;28:184-20316678641 173.ScottLJKeatingGMEntecavir: a review"/>
  <result pre="Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the treatment of chronic hepatitis B" exact="virus infection." post="Clin Ther. 2006;28:184-20316678641 173.ScottLJKeatingGMEntecavir: a review of its use"/>
  <result pre="Clin Ther. 2006;28:184-20316678641 173.ScottLJKeatingGMEntecavir: a review of its use in" exact="chronic hepatitis" post="B. Drugs. 2009;69:1003-103319496629 174.JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudine. Clin Pharmacokinet."/>
  <result pre="Ther. 2006;28:184-20316678641 173.ScottLJKeatingGMEntecavir: a review of its use in chronic" exact="hepatitis" post="B. Drugs. 2009;69:1003-103319496629 174.JohnsonMAMooreKHYuenGJByeAPakesGEClinical pharmacokinetics of lamivudine. Clin Pharmacokinet."/>
  <result pre="lamivudine. Clin Pharmacokinet. 1999;36:41-669989342 175.DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of lamivudine for" exact="chronic hepatitis" post="B infection. N Engl J Med. 1995;333:1657-16617477217 176.DienstagJLSchiffERWrightTLet al.Lamivudine"/>
  <result pre="Clin Pharmacokinet. 1999;36:41-669989342 175.DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of lamivudine for chronic" exact="hepatitis" post="B infection. N Engl J Med. 1995;333:1657-16617477217 176.DienstagJLSchiffERWrightTLet al.Lamivudine"/>
  <result pre="Engl J Med. 1995;333:1657-16617477217 176.DienstagJLSchiffERWrightTLet al.Lamivudine as initial treatment for" exact="chronic hepatitis" post="B in the United States. N Engl J Med."/>
  <result pre="J Med. 1995;333:1657-16617477217 176.DienstagJLSchiffERWrightTLet al.Lamivudine as initial treatment for chronic" exact="hepatitis" post="B in the United States. N Engl J Med."/>
  <result pre="States. N Engl J Med. 1999;341:1256-126310528035 177.LaiCLChienRNLeungNWet al.; collab: Asia" exact="Hepatitis" post="Lamivudine Study GroupA one-year trial of lamivudine for chronic"/>
  <result pre="Asia Hepatitis Lamivudine Study GroupA one-year trial of lamivudine for" exact="chronic hepatitis" post="B. N Engl J Med. 1998;339:61-689654535 178.HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B"/>
  <result pre="Hepatitis Lamivudine Study GroupA one-year trial of lamivudine for chronic" exact="hepatitis" post="B. N Engl J Med. 1998;339:61-689654535 178.HonkoopPde ManRAHeijtinkRASchalmSWHepatitis B"/>
  <result pre="J Clin Pharmacol. 2009;49:725-73419395586 180.KimJWParkSHLouieSGTelbivudine: a novel nucleoside analog for" exact="chronic hepatitis" post="B. Ann Pharmacother. 2006;40:472-47816507625 181.JonesRNelsonMNovel anti-hepatitis B agents: a"/>
  <result pre="Clin Pharmacol. 2009;49:725-73419395586 180.KimJWParkSHLouieSGTelbivudine: a novel nucleoside analog for chronic" exact="hepatitis" post="B. Ann Pharmacother. 2006;40:472-47816507625 181.JonesRNelsonMNovel anti-hepatitis B agents: a"/>
  <result pre="Clin Pract. 2006;60:1295-129916981973 182.LaiCLGaneELiawYFet al.Telbivudine versus lamivudine in patients with" exact="chronic hepatitis" post="B. N Engl J Med. 2007;357:2576-258818094378 183.ChanHLHeathcoteEJMarcellinPet al.Treatment of"/>
  <result pre="Pract. 2006;60:1295-129916981973 182.LaiCLGaneELiawYFet al.Telbivudine versus lamivudine in patients with chronic" exact="hepatitis" post="B. N Engl J Med. 2007;357:2576-258818094378 183.ChanHLHeathcoteEJMarcellinPet al.Treatment of"/>
  <result pre="hepatitis B. N Engl J Med. 2007;357:2576-258818094378 183.ChanHLHeathcoteEJMarcellinPet al.Treatment of" exact="hepatitis" post="B e antigen positive chronic hepatitis with telbivudine or"/>
  <result pre="Med. 2007;357:2576-258818094378 183.ChanHLHeathcoteEJMarcellinPet al.Treatment of hepatitis B e antigen positive" exact="chronic hepatitis" post="with telbivudine or adefovir: a randomized trial. Ann Intern"/>
  <result pre="2007;357:2576-258818094378 183.ChanHLHeathcoteEJMarcellinPet al.Treatment of hepatitis B e antigen positive chronic" exact="hepatitis" post="with telbivudine or adefovir: a randomized trial. Ann Intern"/>
  <result pre="fumarate. Clin Infect Dis. 2003;37:944-95013130407 187.WongSNLokASTenofovir disoproxil fumarate: role in" exact="hepatitis" post="B treatment. Hepatology. 2006;44:309-31316871562 188.ReijndersJGJanssenHLPotency of tenofovir in chronic"/>
  <result pre="in hepatitis B treatment. Hepatology. 2006;44:309-31316871562 188.ReijndersJGJanssenHLPotency of tenofovir in" exact="chronic hepatitis" post="B: mono or combination therapy?J Hepatol. 2008;48:383-38618191272 189.GitmanMDHirschwerkDBaskinCHSinghalPCTenofovir-induced kidney"/>
  <result pre="hepatitis B treatment. Hepatology. 2006;44:309-31316871562 188.ReijndersJGJanssenHLPotency of tenofovir in chronic" exact="hepatitis" post="B: mono or combination therapy?J Hepatol. 2008;48:383-38618191272 189.GitmanMDHirschwerkDBaskinCHSinghalPCTenofovir-induced kidney"/>
  <result pre="chronic hepatitis B: mono or combination therapy?J Hepatol. 2008;48:383-38618191272 189.GitmanMDHirschwerkDBaskinCHSinghalPCTenofovir-induced" exact="kidney injury." post="Expert Opin Drug Saf. 2007;6:155-16417367261 190.GuptaSKTenofovir-associated Fanconi syndrome: review"/>
  <result pre="event reporting system. AIDS Patient Care STDS. 2008;22:99-10318260800 191.SchmidSOpravilMModdelMet al.Acute" exact="interstitial nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
  <result pre="reporting system. AIDS Patient Care STDS. 2008;22:99-10318260800 191.SchmidSOpravilMModdelMet al.Acute interstitial" exact="nephritis" post="of HIV-positive patients under atazanavir and tenofovir therapy in"/>
  <result pre="AIDS Patient Care STDS. 2008;22:99-10318260800 191.SchmidSOpravilMModdelMet al.Acute interstitial nephritis of" exact="HIV-positive" post="patients under atazanavir and tenofovir therapy in a retrospective"/>
  <result pre="a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450:665-67017464512 192.KapitsinouPPAnsariNAcute" exact="renal failure" post="in an AIDS patient on tenofovir: a case report."/>
  <result pre="tenofovir: a case report. J Med Case Reports. 2008;2:9418373879 193.ZimmermannAEPizzoferratoTBedfordJMorrisAHoffmanRBradenGTenofovir-associated" exact="acute" post="and chronic kidney disease: a case of multiple drug"/>
  <result pre="case report. J Med Case Reports. 2008;2:9418373879 193.ZimmermannAEPizzoferratoTBedfordJMorrisAHoffmanRBradenGTenofovir-associated acute and" exact="chronic" post="kidney disease: a case of multiple drug interactions. Clin"/>
  <result pre="Dis. 2006;42:283-29016355343 194.FooteBCSpoonerLMBelliveauPPBoceprevir: a protease inhibitor for the treatment of" exact="chronic hepatitis" post="C [Epub ahead of print August 9, 2011]. Ann"/>
  <result pre="2006;42:283-29016355343 194.FooteBCSpoonerLMBelliveauPPBoceprevir: a protease inhibitor for the treatment of chronic" exact="hepatitis" post="C [Epub ahead of print August 9, 2011]. Ann"/>
  <result pre="August 9, 2011]. Ann Pharmacother. doi:10.1345/aph.1P744 195.PoordadFMcConeJJrBaconBRet al.Boceprevir for untreated" exact="chronic" post="HCV genotype 1 infection. N Engl J Med. 2011;364:1195-120621449783"/>
  <result pre="N Engl J Med. 2011;364:1195-120621449783 196.BaconBRGordonSCLawitzEet al.Boceprevir for previously treated" exact="chronic" post="HCV genotype 1 infection. N Engl J Med. 2011;364:1207-121721449784"/>
  <result pre="HCV genotype 1 infection. N Engl J Med. 2011;364:1207-121721449784 197.PawlotskyJMChevaliezSMcHutchisonJGThe" exact="hepatitis" post="C virus life cycle as a target for new"/>
  <result pre="a target for new antiviral therapies. Gastroenterology. 2007;132:1979-199817484890 198.SarrazinCKiefferTLBartelsDet al.Dynamic" exact="hepatitis" post="C virus genotypic and phenotypic changes in patients treated"/>
  <result pre="telaprevir. Gastroenterology. 2007;132:1767-177717484874 199.McHutchisonJGEversonGTGordonSCet al.Telaprevir with peginterferon and ribavirin for" exact="chronic" post="HCV genotype 1 infection. N Engl J Med. 2009;360:1827-183819403902"/>
  <result pre="2009;360:1827-183819403902 200.HézodeCForestierNDusheikoGet al.Telaprevir and peginterferon with or without ribavirin for" exact="chronic" post="HCV infection. N Engl J Med. 2009;360:1839-185019403903 201.JacobsonIMMcHutchisonJGDusheikoGet al.Telaprevir"/>
  <result pre="N Engl J Med. 2009;360:1839-185019403903 201.JacobsonIMMcHutchisonJGDusheikoGet al.Telaprevir for previously untreated" exact="chronic hepatitis" post="C virus infection. N Engl J Med. 2011;364:2405-241621696307 202.ZeuzemSAndreonePPolSet"/>
  <result pre="Engl J Med. 2009;360:1839-185019403903 201.JacobsonIMMcHutchisonJGDusheikoGet al.Telaprevir for previously untreated chronic" exact="hepatitis" post="C virus infection. N Engl J Med. 2011;364:2405-241621696307 202.ZeuzemSAndreonePPolSet"/>
  <result pre="Med. 2009;360:1839-185019403903 201.JacobsonIMMcHutchisonJGDusheikoGet al.Telaprevir for previously untreated chronic hepatitis C" exact="virus infection." post="N Engl J Med. 2011;364:2405-241621696307 202.ZeuzemSAndreonePPolSet al.Telaprevir for retreatment"/>
 </snippets>
</snippetsTree>
